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2 
Abstract 
This thesis outlines progress towards the synthesis of aristopyridinone A.  
Aristopyridinone A is a compound isolated from the traditional Chinese medicine plant 
Aristolochia manshuriensis.  While the plant has been used in a variety of medicinal capacities, 
the biological activity of aristopyridinone A is unknown.  The synthetic pathways presented in 
this thesis expand on previous work using a merged Diels Alder [4+2] cycloaddition and 
cycloreversion strategy to form the 2-pyridone core of the aristopyridinone A molecule.  These 
studies also explore the chemistry of the inter-molecular Diels-Alder reaction using a 
diketopiperazine-derived azadiene. 
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Chapter One 
Introduction: 
The use of alternative medicine, like traditional Chinese medicine, is becoming 
increasingly popular in our society.  While not based on scientific evidence, many alternative 
medicinal remedies do show some healing or restorative effects.  The plant Aristolochia 
manshuriensis has historically been used as an anti-inflammatory, an antibacterial, and as a cure 
for snakebites.3  However, its toxicity and carcinogenic properties have led to the end of its use 
in traditional Chinese medicine, and prompted isolation studies of active compounds.  Renewed 
isolation efforts have yielded a variety of compounds, including artistopyridinone A (Figure 
1.1).3  While its bioactivity is unknown, the 2-pyridone core of aristopyridinone A is found in 
many biologically active compounds10, and thus makes the compound an attractive target for 
chemical synthesis. 
 
Figure 1.1 Aristopyridinone A with 2-pyridone core highlighted in red
NH
OHO
HO
7 
Traditional Chinese Medicine and Aristolochia manshuriensis: 
The use of plants as medicine dates back to the beginning of humankind. The earliest 
records of medical therapeutics come from an Egyptian scroll dating back to 1500 B.C.E. and 
detail herbal remedies for a variety of ailments.  The first synthetic drug was not discovered until 
1869.11  Today, the majority of clinically viable drugs are either directly or indirectly derived 
from natural sources.1  Aspirin, one of the most widely distributed drugs in the world, is a 
modified version of salicylic acid, the major active component in the centuries-old, herbal 
remedy for fevers: willow bark tea.11  Despite the rise of the pharmaceutical industry, our 
continued confidence in plant remedies is seen clearly in the current prevalence of alternative 
medicine.  The use of traditional Chinese medicine, a practice steeped in history and tradition, 
continues to be the leading source of alternative remedies in our society.21 In China alone, more 
than 3000 hospitals provide traditional Chinese remedies to 234 million people every year.4 
Traditional Chinese medicine dates back to 475 BCE, and continues to function on the 
importance of balance between different theories of the body.  These theories began as a 
compilation of six meridians that governed one’s well being, and have since been summarized 
into the theories of yin, yang, and chi.21  Chi is the life force of the human body and travels 
through the body via the blood stream.  The balance of chi in the five major organs, the heart, 
liver, spleen, lungs, and kidneys, is crucial for health of the whole body.  Similar to the humors 
theory of medicine from medieval Western Europe, yin and yang represent wet, cold and female 
and hot, dry and male, respectively.  It is the balance of these two forces that maintains health.1  
Practitioners of traditional Chinese medicine believe that disease is caused by either too much 
yin or too much yang, and will prescribe herbal treatments aimed at restoring levels of yin and 
yang.  This is also known as the warm disease theory of medicine.  There are extensive records 
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describing the classification of diseases as hot or cold, and which plants or plant mixtures are 
necessary to regain balance of yin and yang.21  Currently, the compilation of plants used in 
traditional Chinese medicine is published as the Chinese Materia Medica, and has been used by 
scientists as a resource for modern drug discovery.1   It is also used to track toxicities of plants 
and efficacy of traditional treatments, as in the case of Aristolochia manshuriensis. 
Aristolochia manshuriensis (Mu Tong or Guanmutong) is a leafy, shrub-like plant 
belonging to the Aristolochiaceae family found in northeastern China and Korea.3 The climbing 
vine thrives in warmer, moist climates where they can be exposed completely to the sun.  
Horticulturalists now use the plant in landscaping, and it can now be found in parks and 
backyards around the world.9  It is believed that the use of the stem of A. manshuriensis in 
Chinese folk medicine can be traced to the 3rd century BCE.  It was originally classified as a 
damp-draining herb, meaning that it helps with diseases associated with too much yin, and was 
administered as a tea brewed from the stems of the plant.  Despite current knowledge of its 
nephrotoxicity, early Chinese documents fail to mention the high toxicity of Mu Tong, leading 
historians to conclude that the plant source of the herbal mix prescribed as Mu Tong has possibly 
changed throughout centuries.  The inclusion of A. manshuriensis in lieu of a related species 
would change the alkaloid composition of the herbal medicine enough to affect toxicity.  This is 
the most probable reason that toxicity and compound isolation studies of Mu Tong only began at 
the end of the 20th century.22  
Widely distributed as an anti-inflammatory and diuretic, approximately twenty tons of A. 
manshuriensis were exported from China every year from 1984-2004.9 The first reported cases 
of nephropathy related to the ingestion of A. manshuriensis came from Belgium in 1993, 
followed by reports of renal failure associated with the herb in Japan. Reports of A. 
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manshuriensis-associated renal and urothelial cancers subsequently followed.19 Follow-up 
studies attribute this nephrotoxicity to the high concentrations of aristolochic acids found in the 
plant.13  One toxicity experiment found that the dose of an alcoholic extract of A. manshuriensis 
lethal to 50% of animals is 15.5 ± 0.6 g/kg in mice.22  A second experiment found an LD50 of 
29.1 ± 3.71 g/kg.  This study also found differing lethality of A. manshuriensis depending on the 
region it is grown, pointing to the environmental effects of toxin concentrations in the plant and 
potentially explaining the two different LD50 results.9  In 2003, the use of Aristolochia 
manshuriensis was banned in the mainland of China.12 By 2007, most countries had banned the 
use of Aristolochia manshuriensis and other aristolochic acid containing plants.2  
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Aristolochic acids and derivatives: 
Aristolochic acids were isolated from A. manshuriensis in 1994, but were not categorized 
as the toxic agents until 2002.  While concentrations depend on the region in which the plant is 
grown, aristolochic acids are the dominant metabolites in A. manshuriensis, making up 0.45% to 
1.06% of the plant by weight.9 They are currently ranked among the top 2% of most potent 
carcinogens.2  Comparisons of the chemical components of plants from the Aristolochiaceae 
family, all known to be toxic, and plants from the Akebia family, a benign herb with anti-
inflammatory properties found aristolochic acids and their ester and amide derivatives (Figure 
1.2) to be the major component difference and thus the basis of Aristolochiaceae 
nephrotoxicity.13  Toxicity studies using Wistar rats and NMRI (Naval Medical Research 
Institute) mice found an LD50 of 56 to 203 mg/kg orally and 38 to 83 mg/kg intravenously.  The 
large ranges are accounted for by species and sex of animal.  Renal function was severely 
impaired at daily dosages as low as 10 mg aristolochic acid per kg of body weight.4  
 
Histological analysis of organ tissue post-treatment with Aristolochia manshuriensis or 
aristolochic acids shows extensive damage to the kidneys in the form of renal tubular necrosis.  
Induced apoptosis of the tubular cells is the most probable mechanism for the resulting necrosis.  
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Figure 1.2 Structures of aristolochic acids (1), aristolochic esters (2), aristolamides (3), aristolactams (4)3
O
O
COOCH3
R1
R2 OCH3
R1 = NO2  R2 = H
R1 = H      R2 = OCH3
R1 = H      R2 = H
(2)
O
O
R
NH2
O
R = H
R = OCH3
(3)
O
O NH
O
R
R = H
R = OCH3
R = OH
(4)
11 
Longer exposure to aristolochic acids also results in tubular atrophy and interstitial fibrosis. 
Mitochondrial damage and deactivation of antioxidative enzymes due to tubular atrophy impair 
tubular cell regeneration and lead to the formation of the fibroblasts.  Although it is unknown 
why these compounds preferentially affect the kidneys, it is hypothesized that genetic expression 
of aristolochic acid transporters is up regulated in the kidneys.13   Also of concern are the 
relatively higher concentrations of aristolochic acid found in the lungs of rats.9 While there are 
no known reports of lung disease associated with aristolochic acid, it remains a potential side 
effect of using aristolochic acid containing substances, like Aristolochia manshuriensis.  
Aristolochic acids affect gene expression, and therefore cell behavior.  Aristolochic acids, 
in the form of aristolactams, are able to form covalent linkages to DNA (see Figure 1.3).  Human 
enzymes p450 1A1 and 1A2 activate the aristolactam, forming a cyclic nitrenium ion that then 
reacts with the amino groups of adenine and guanine. These DNA adducts assist in DNA 
fragmentation, forcing the cell to lyse, and cause chromosomal damage, interfering with correct 
chromosomal exchange during the cell cycle.  The nitro group of aristolochic acids is important 
in the compounds’ mutagenetic effect.  Reduction of the nitro group in vivo to form the 
aristolactam functionality activates the metabolite for DNA addition.18  The mutation frequency 
of mitotic genes in cells treated with aristolochic acid increases by 10 to 33-fold.  Correlation 
studies between mutagenicity and carcinogenicity reveal that aristolochic acids induce tumor 
formation through this increased mutation frequency.2  Activation of the H-ras oncogene and 
inactivation of the p53 tumor suppressor gene by A:T ! T:A mutations have been implicated in 
aristolochic acid-initiated tumors.14   
12 
 
 
However, the increased mutation frequency does not fully explain the tissue-specific 
carcinogenicity of aristolochic acids.  A comparison of gene expression in liver and kidney cells 
found significant mutations in kidney genes associated with defense response, apoptosis, and 
immune response, but these mutations were absent in the liver cells.  It is suggested that 
Figure 1.3 Activation of aristolochic acids and aristolactams and conjugation with DNA2
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conjugation of aristolochic acids in the liver and other tissues are exported into the bloodstream, 
where they are then taken up by renal and urothelial cells, attributing to the specificity of cancer 
these compounds cause.2 Transcription of genes encoding sulfotransferases, SULTs, is also 
increased in renal and urothelial cells in the presence of aristolochic acids.  This corresponds 
with data supporting evidence that phase II metabolites of aristolochic acids have higher 
mutagenic and cytotoxic potential.18   
The dangers of aristolochic acids encouraged scientists to focus on the isolation of other 
biologically active molecules in the Aristolochia manshuriensis stem.  A study in 2010 isolated 
two potential antitumor compounds, both phenanthrene derivatives (Figure 1.4, 1a,b).  
Compounds 1a and 1b were isolated 0.00892% and 0.00446% by weight from the Aristolochia 
manshuriensis stems.  Both compounds showed significant CDK-2 inhibition.  CDK-2, cyclin 
dependent kinase 2, is a cell cycle regulatory enzyme and thus an attractive potential target for 
anticancer research.8 Further extraction efforts led to the isolation of ferulic acid (Figure 1.4, 2a), 
0.00100% by weight, and p-hydroxycinnamic acid (Figure 1.4, 2b), 0.00150% by weight.  
Ferulic acid is a well-known antibacterial, and may account for some of Aristolochia 
manshuriensis’s antibacterial properties.  Hydroxycinnamic acids are antioxidants derived from 
cinnamic acid.  They are found in a wide variety of plants and foods.12 A study in 2011 isolated 
two compounds (Figure 1.4, 3a,b) from Aristolochia manshuriensis that showed significant anti-
inflammatory activity by inhibiting neutrophil elastase release and superoxide anion generation.  
The chemists were surprised to discover that they were aristolochic acid derivatives because this 
was the first time that aristolochic acid derivatives had shown any anti-inflammatory response.  
Aristolamide 3a was isolated 0.00198% by weight from the Aristolochia manshuriensis stems.  
Aristolactam 3b was isolated 0.00197% by weight from the stems.3 
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Figure 1.4 Biologically active molecules isolated from Aristolochia manshuriensis
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Aristopyridinone A: 
The 2011 study by Chung, et al. that isolated two anti-inflammatory compounds from 
Aristolochia manshuriensis also isolated another novel molecule, which was named 
aristopyridinone A (see Figure 1.1).  Unfortunately, insufficient amounts of the compound 
prevented evaluation of bioactivity.3 The structure of aristopyridinone A is significantly different 
from the other molecules isolated from Aristolochia manshuriensis, which makes it difficult to 
predict its potential bioactivity although the 2-pyridone scaffold is found in many biologically 
active compounds.10 With the aim of exploring its biological activity, we designed a synthetic 
route towards aristopyridinone A, which is the focus of this thesis.! 
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Synthetic strategies for making the 2-Pyridone scaffold: 
 Pyridone alkaloids provide a rich diversity of compounds of varying biological activity.  
The first isolated pyridone was the poison ricinine, isolated in the 19th century from the castor 
bean, although scientists didn’t verify the structure until 1904 (Figure 1.5).10  Camptothecin, a 
potent anti-cancer drug, is a natural product isolated from the tree Camptheca acuminata.  
Topotecan, a semisynthetic derivative of camptothecin, continues to be used in the treatment of 
certain colon and ovarian cancers.6  Huperzine A is a current lead compound for the treatment of 
Alzheimer’s disease and age-related memory loss.  Leporin A shows anti-insect properties 
against the corn earworm Helicoverpa 200.  The anti-fungal compound ilicicolin H is isolated 
from the fungus Cylindrocladium ilicicola.20  The potent biological activity of 2-pyridones is 
partly attributed to the amide functionality that can structurally mimic a peptide backbone.6  The 
broad array of applications of this medicinally privileged scaffold makes this chemical 
functionality an important and well-studied target for medicinal chemists. 
 
Figure 1.5 2-pyridone examples
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 Several synthetic approaches exist to construct the 2-pyridone scaffold, but all strategies 
can be separated into two main categories: generation of the 2-pyridone ring system from other 
cyclic systems or generation of the 2-pyridone ring system by condensation of acyclic systems.7  
The categories can be further classified depending on starting material or bond formed during 
cyclization.20 
Pyridines and 2-pyranones comprise the main heterocycle starting materials for the 
synthesis of 2-pyridones, although 5-member heterocycles are also used.  Oxidation of pyridines 
(Scheme 1.1a) and hydrolysis of 2-halopyridines (Scheme 1.1b) are common methods of 2-
pyridone preparation.20   
 
The reaction of 2-pyranone derivatives with urea affords a 1:1 mixture of the 
corresponding 2-pyridone and 2-aminopyridine (Scheme 1.2).  This occurs through a 
nucleophile-induced ring rearrangement.  Replacement of the nitrile group with a 
methoxycarbonyl yields the 2-pyridone product exclusively.5   
 
Scheme 1.1 Synthesis of 2-pyridones from pyridine starting materials
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Scheme 1.2 Synthesis of 2-pyridones from 2-pyranones
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Multiple strategies for synthesizing 2-pyridones from 5-member heterocycles utilize 
cycloaddition reactions.20  One example is the synthesis developed by Padwa and colleagues, 
transforming imidosulfoxides through a Pummerer cyclization-deprotonation-cycloaddition 
cascade reaction (Scheme 1.3a).16  This reaction works via an isomünchnone intermediate that 
can be trapped with a variety of dipolarophiles.  Acidic cleavage of the cycloadduct yields the 
corresponding 2-pyridone.20  An alternative pathway using 5-member heterocycle starting 
materials utilizes 5-silylmethylisoxazole as a !-enaminoketone source after catalytic 
hydrogenation, which affords 2-pyridones upon treatment with nucleophiles like malononitrile 
(Scheme 1.3b).7   
 
There are a wide variety of syntheses that generate the 2-pyridone ring system via 
condensation strategies.  One of the first syntheses to utilize condensation chemistry to construct 
the 2-pyridone scaffold was the racemic total synthesis of tenellin by David Williams and 
colleagues, which created the saturated heterocycle by Dieckmann condensation (Scheme 1.4).  
Further oxidation establishes the aromatic 2-pyridone core.10  Synthetic strategies involving an 
aldolic condensation to form the 2-pyridone continue to be widely used.20 
Scheme 1.3 Synthesis of 2-pyridones from 5-member heterocycles
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Isocyanates have also shown to be starting materials for 2-pyridones through multiple 
pathways.  They will undergo a transition metal-catalyzed cyclotrimerization with two alkyne 
moieties to deliver substituted 2-pyridones (Scheme 1.5a).20 Vinyl isocyanates will react with 
enamines or enolates to afford an enamide intermediate that will cyclize to the 2-pyridone 
heterocycle, as demonstrated in the synthesis of pyridovericin by Zhang and colleagues (Scheme 
1.5b).10    
 
Palladium chemistry has been utilized in the construction of 2-pyridones.  4,6-
disubstituted-2-pyridones can be synthesized from (Z)-3-substituted-3-iodoprop-2-enamides and 
tributylstannylallenes.7  A proposed mechanism for the reaction is shown in Scheme 1.6.  
Palladium is also the catalyst for the decarboxylative carbonylation of 5-vinyloxazolidin-2-ones 
to afford tri-substituted 2-pyridones.20 
Scheme 1.4 2-pyridone formation in Williams' 1982 synthesis of tenellin
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Scheme 1.5 Synthesis of 2-pyridones from isocyanate starting materials
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Other advancements in the synthesis of 2-pyridones include strategies involving a !-
lactam precursor6,10, Michael addition with acetonitrile derivatives20, and a Diels-Alder 
cycloaddition.7,20  The hetero-Diels-Alder reaction between azadienes and a variety of 
dieneophiles has delivered a range of pyridone products (Scheme 1.7a).20  A vinylthioamide 
starting material will undergo a [4+2] cycloaddition with a ketene dieneophile upon activation 
with methyl iodide to afford the corresponding 2-pyridone (Scheme 1.7b).7 
 
Scheme 1.6 Reaction mechanism for synthesis of 2-pyridones via palladium catalyzed heteroannulation
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Scheme 1.7 Synthesis of 2-pyridones via a Diels-Alder cycloaddition
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A novel synthetic strategy reported by Margrey, Hazzard, and Scheerer accesses the 2-
pyridone structure through the cycloreversion of [2.2.2]-diazabicyclic alkene diketopiperazines 
(Scheme 1.8).  Original work by Sammes and colleagues showed the conversion of 2-
pyrazinones to 2-pyridones via a cycloaddition with alkyne substrates and subsequent extrusion 
of isocyanate to form the planar aromatic heterocycle.  Margrey and colleagues used two 
different diketopiperazines as starting materials and were able to perform selective 
cycloreversion of [2.2.2] cycloadducts for 2-pyridone products through activation of one aza 
bridging function.  This method was shown to be viable with a variety of intramolecular Diels-
Alder cycloadducts.  An intermolecular Diels-Alder approach using the symmetrical, electron-
deficient dieneophile dimethyl acetylenecarboxylate (DMAD) afforded the corresponding 2-
pyridone, but further investigation of the intermolecular Diels-Alder reaction using 
diketopiperazine-derived azadienes has yet to be explored.15 
Scheme 1.8 Synthesis of 2-pyridones via cycloreversion of [2.2.2]-bicycloalkene diketopiperazines
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Conclusion: 
The potent biological activity of 2-pyridone compounds makes accessing the chemical 
scaffold of interest to synthetic chemists.  While several methods exist for making 2-pyridones, 
new synthetic strategies for their preparation are relevant and broaden the array of compounds 
that are synthetically accessible.  The synthesis of aristopyridinone A expands on work done by 
Margrey, Hazzard, and Scheerer on the synthesis of 2-pyridones via a merged Diels-Alder [4+2] 
cycloaddition and cycloreversion.  Of note is the intermolecular Diels-Alder reaction to form the 
[2.2.2]-diazabicyclic cycloadduct.  Aristopyridinone A is a compound of particular interest due 
to its unexplored biological activity and its isolation from the traditional Chinese medicinal herb 
A. manshuriensis. 
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Chapter Two 
Introduction: 
Inspired by the 2014 study by Margrey, Hazzard, and Scheerer, we began developing a 
synthesis towards aristopyridinone A.  Our general strategy (see Scheme 2.1) accesses the 2-
pyridone moiety through a cycloreversion of a [2.2.2]-diazabicyclic alkene. While previous work 
focused on an intramolecular Diels-Alder [4+2] cycloaddition to form the desired cycloadduct, 
our route probes the chemistry of the intermolecular Diels-Alder reaction.  In particular, our 
route explores the regioselectivity of the Diels-Alder [4+2] cycloaddition from a 
diketopiperazine-derived azadiene.  Our studies have led to a nine-step proposed synthesis of 
aristopyridinone A from a dimethoxybenzyl (DMB) protected diketopiperazine starting material. 
Scheme 2.1 General strategy toward the synthesis of aristopyridinone A
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Diels-Alder cycloaddition: 
 The identification of products arising from the reaction of cyclopentadiene and quinone 
in 1928 by Otto Diels and Kurt Alder (Scheme 2.2) was the first description of the [4+2] 
cycloaddition that was eventually named the Diels-Alder reaction.5  The 4 and 2 identify the 
number of ! electrons involved in the electronic rearrangement, as well as the number of atoms 
originating the unsaturated six-member ring.  The pericyclic reaction occurs between a 
conjugated diene (4 ! electrons) and a dieneophile (2 ! electrons).  The classic Diels-Alder reacts 
butadiene with ethylene to afford cyclohexene (Scheme 2.3a).  There is a huge diversity of 
dienes and dieneophiles that will undergo a Diels-Alder reaction, but electron-donating 
substituents on the diene and electron-withdrawing substituents on the dieneophile provide faster 
cycloaddition.  Substituted dienes and dieneophiles can also provide regioselectivity for 
intermolecular cycloadditions (Scheme 2.3b,c).3  Recent advancements have studied the hetero-
Diels-Alder reaction, which utilizes nitrogen and oxygen-containing diene and dieneophiles.2 
 
Scheme 2.2 Discovery of the Diels-Alder [4+2] cycloaddition5
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Diels-Alder reactions are described by a concerted, pericyclic mechanism (Scheme 2.4).  Two 
different pathways have been proposed to explain the concerted transition state: simultaneous 
formation of new bonds or the formation of one " bond induces electronic rearrangement.  The 
nature of the reagents and reaction conditions will determine the reaction pathway.3   The 
concerted cycloaddition mechanism also means that the Diels-Alder reaction is stereospecific, 
and is capable of installing up to four new stereogenic centers.  Stereoselectivity of the Diels-
Alder reaction is often rationalized from the endo transition state, which is stabilized by 
favorable interactions the ! electron system of the dieneophile substituent and the ! electron 
system of the diene (Scheme 2.5).2  
 
Scheme 2.3 Simple Diels-Alder reaction examples
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Scheme 2.4 Concerted mechanism of the Diels-Alder reaction
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Electronically, the Diels-Alder reaction proceeds through the interaction of the 4 ! 
electron system of the diene and the 2 ! electron system of the dieneophile.  The energy 
difference between the diene’s highest occupied molecular orbital (HOMO) and the 
dieneophile’s lowest unoccupied molecular orbital (LUMO) helps establish the rate of 
cycloaddition.  These HOMO-LUMO interactions can be categorized into three different types: 
the “normal” HOMOdiene-controlled cycloaddition, the neutral cycloaddition, and the “inverse 
electron demand” LUMOdiene-controlled cycloaddition (Figure 2.1).2  Electronic and structural 
features of the diene and dieneophile determines type of cycloaddition.  
Scheme 2.5 Endo v. exo transition states
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In the original 1928 communication, Diels and Alder understood the implications of their 
[4+2] cycloaddition for natural product synthesis, noting, “Thus it appears to us that the 
possibility of synthesis of complex compounds related to or identical with natural products such 
as terpenes, sesquiterpenes, perhaps even alkaloids, has been moved to the near prospect.”1  
However, it was not until 1952, when Woodward and colleagues described a novel synthesis of 
steroid cortisol and cortisone involving a Diels-Alder reaction, that the [4+2] cycloaddition 
entered the mainstream set of reactions for total synthesis.5  The Diels-Alder reaction is now a 
widely used, versatile method for constructing six-membered rings as a part of simple and 
complex molecules. 
Figure 2.1 HOMO and LUMO configurations of three cycloaddition types2
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Methods and Results: 
In order to help determine optimal Diels-Alder reaction conditions and to gain a baseline 
for the regioselectivity of the cycloaddition, we created a model system using benzaldehyde in 
our aldol condensation step and propargyl alcohol as our dieneophile (Scheme 2.6 ).   
 
Our starting material is the dimethoxybenzyl (DMB) protected diketopiperazine 1, 
prepared in 4 steps (55% overall yield) from glycine methyl ester.4  Enolization of the DKP 
substrate was accomplished using the amide base LiHMDS, followed by aldol addition into 
Scheme 2.6 Synthetic route for model system
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benzaldehyde. Acylation of the !-hydroxy intermediate preceded elimination to the exocyclic 
azadiene 2 upon exposure to DBU.  The aldol condensation, acetylation, and elimination were 
accomplished in a “one-pot” reaction.  Azadiene 2 was isomerized to the endocyclic diene under 
basic conditions, and underwent a Diels-Alder [4+2] cycloaddition with propargyl alcohol as the 
dieneophile at 110 ºC to deliver cycloadducts 3 and 4 as an inseparable 1:3 mixture. Following 
precedent from Margrey, Hazzard, and Scheerer, the lactim O-methyl ether of 3 and 4 was 
converted the lactam in 5 and 6.  In the lactam form, the two regioisomers were separable.  Upon 
activation of the aza bridging function (Ac2O, pyr, 110 ºC), we were able to deliver the retro 
Diels-Alder products, DMB protected pyridones 7 and 8, diverging from precedent, which 
required more vigorous thermolysis conditions.   
Cycloadduct 3 and the derived 3,4-disubstituted pyridone 7 possess the structural 
relationship apparent in aristopyridinone A.  On our real system, we chose ethyl propiolate as the 
dieneophile (Scheme 2.7) with the hope that the reversed electronics would provide reversed 
regioselectivity of the Diels-Alder reaction.   
 An aldol condensation was performed with DMB-protected DKP 1 and aldehyde 9, which 
can be prepared by ozonolysis of 4-allylanisole (63% yield).  Acetylation of the !-hydroxy 
intermediate immediately followed, delivering product 10.  The instability of endocylic azadiene 
11 to purification required us to stop the previously “one pot” reaction at the acetylated 
intermediate.  Elimination and isomerization of 10 yielded azadiene 11 upon exposure to DBU.   
The exocyclic azadiene was not observed.  Product 11 was immediately submitted to an 
intermolecular Diels-Alder cycloaddition, using ethyl propiolate as the dieneophile, delivering 
cycloadducts 12 and 13 as an inseparable mixture (ratio 1:2).  The desired regioisomer was again 
the minor product of [4+2] cycloaddition.  The lactim O-methyl ether in 12 and 13 was 
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converted to the lactam in 14 and 15.  The regioisomers 14 and 15 were still inseparable. 
 
Scheme 2.7 First proposed synthesis of aristopyridinone A and synthesis of its C-isomer
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 Thermolysis of the mixture of regioisomers 14 and 15 (Ac2O, 140ºC, 2d) afforded two 
separable products 16 and 17.  Analysis of 1H NMR spectra led us to conclude that one product 
was due to the desired cycloreversion reaction, and the other product was due to a 
rearrangement.  HMBC/HSQC analysis of the retro Diels-Alder product proved to be 3,5-
disubstituted pyridone 16.  Proposed mechanisms for the rearrangement (Equation a) and 
successful cycloreversion (Equation b) are shown in Scheme 2.8.  
 
 The divergent reactivity with allylic acetate versus the unsaturated ester possibly implies a 
highly asynchronous transition state for the retro Diels-Alder reaction.  For the unsaturated ester 
substrate, as the carbon-nitrogen bond of the imide breaks, elimination of the bridgehead 
hydrogen, yielding rearrangement, appears faster than the carbon-carbon bond cleavage, yielding 
cycloreversion.  The indicated bridgehead hydrogen in cycloadduct 14 (Scheme 2.8a) is more 
acidic than the bridgehead hydrogen in cycloadduct 5 (Scheme 2.8b) because it is doubly 
activated located both #- to the imide and $- to the unsaturated ester. 
 Although cycloreversion conditions yielded the 3,5-disubstituted pyridone, we continued 
Scheme 2.8 Rearrangement and cycloreversion mechanisms
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functional group manipulation to afford C-isomer aristopyridinone A.  Deprotection of the 
pyridone 16 was accomplished on exposure to TFA in CH2Cl2 and Et3SiH (microwave heating) 
to afford pyridone 18.  The ethyl ester functionality in 18 was then reduced using LiAlH4, 
affording 4-hydroxymethyl pyridone 19.   Cleavage of the methyl ether in 19 was attempted 
under basic and neutral conditions to avoid ionization of the alcohol.  However, attempts at 
demethylation using LiI in lutidine and TMSCl-NaI in acetonitrile provided multiple products 
and poor yields, so an alternative route was used.  Demethylation of pyridone 18 was 
accomplished using BBr3 in dichloromethane starting at -78 ºC and warming to room 
temperature to afford pyridone 20.  Reduction of the ethyl ester using LiAlH4 delivered C-isomer 
aristopyridinone A (product 21) in 2.2% overall yield. 
 The lack of regioselectivity of the intermolecular Diels-Alder led us to investigate 
another dieneophile of differing electronic properties (Scheme 2.9).  Azadiene 11 was submitted 
to a Diels-Alder reaction using methyl nitroacrylate as the dieneophile starting at 0 ºC and 
warming to room temperature overnight to provide the separable cycloadducts 22 and 23 in a 1:1 
regioisomeric ratio.  Elimination of the nitro group was accomplished on both regioisomers using 
DBU to deliver products 24 and 25.  In the hopes of avoiding rearrangement of the desired 
cycloadduct regioisomer, lactim 25 was demethylated to lactam 26 and reduction of the methyl 
ester was attempted using DIBAl-H.  Unfortunately, efficient reduction could not be easily 
realized. 
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A summary of our efforts towards cycloreversion is shown in Scheme 2.10.  The 
presence of an unsaturated ester in the 4-C position of the cycloadduct inhibits cycloreversion, 
instead favoring a ring-opening rearrangement. Our model system showed that saturation at the 
allylic position, in this case the allylic acetate group, in the cycloadduct favors the retro Diels-
Alder reaction over rearrangement under similar conditions.  However, reduction of the ester 
functionality to the corresponding saturated allylic position proved difficult, and was not a 
promising direction for our synthesis.  
Scheme 2.9 Synthetic strategy towards aristopyridinone A using methyl nitroacrylate dieneophile
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With these results in mind, we decided that the most direct route to aristopyridinone A 
was performing the Diels-Alder with propargyl alcohol and carrying through the cycloreversion 
and functional group manipulation on the minor isomer (Scheme 2.11). 
Scheme 2.10 Summary of cycloreversion chemistry
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The acetylated diketopiperazine derivative 10 was reacted with DBU and propargyl 
alcohol at 110 ºC, creating the endocyclic azadiene in situ and undergoing the Diels-Alder [4+2] 
cycloaddition to afford products 27 and 28 as an inseparable 1:4 mixture.  Conversion of the 
lactim ether to the lactam in 29 and 30 failed to improve separation of the cycloadducts.  
Scheme 2.11 Synthesis of aristopyridinone A
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Thermolysis of the mixture of regioisomers 29 and 30 (Ac2O, pyr, 110 ºC, 48h) delivered the two 
DMB protected pyridones 31 and 32.  The mixture of regioisomers remained difficult to 
separate; however, cleavage of the acetate group improved separation and products 33 and 34 
were separated using flash column chromatography. 
Following precedent from the C-isomer aristopyridinone A synthesis  (Scheme 2.7), and 
once again using the major regioisomer to validate our deprotection strategy, acidic deprotection 
of the pyridone 32 and 34 was attempted.  However, loss of the acetate or hydroxy group was 
observed in each case.  Therefore, we moved to an oxidative cleavage of the DMB protecting 
group (Scheme 2.12).  Oxidation of pyridone 34 with CAN yielded multiple products with very 
little detection of desired product by 1H NMR spectroscopy. A second attempt at oxidative 
cleavage of the DMB group with CAN of 34 afforded primary oxidation product 35 and a 
secondary oxidation product 36.  Further oxidation of 36 failed to afford the de-protected 
pyridone.  Oxidation of 34 with DDQ afforded product 35, but did not cleave the DMB group 
upon further oxidation. 
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Given these difficulties with oxidative cleavage, we returned to an acidic cleavage of the 
DMB group (Scheme 2.11).  The benzylic alcohol of pyridone 34 was oxidized to the aldehyde 
with MnO2 to deliver product 35 in 87% yield.  Deprotection of 35 was accomplished with 
microwave heating (130 ºC, 30 min) in TFA and CH2Cl2.  Successful deprotection of 35 gave us 
the confidence to follow the same sequence with our desired regioisomer 33.  Product 33 was 
oxidized with MnO2 to yield pyridone 37, which was submitted to microwave heating in TFA 
and CH2Cl2 to afford de-protected pyridone 38.  Demethylation of the phenolic ether was carried 
out with BBr3 to provide 39.  Reduction of the aldehyde of 39 to the alcohol was accomplished 
using NaBH4 to afford aristopyridinone A (40). 
Scheme 2.12 Problems with cleavage of the DMB protecting group
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Discussion: 
The synthesis discussed details our studies directed toward the first synthesis of 
aristopyridinone A and its C-isomer.  Synthesis of C-isomer aristopyridinone was accomplished 
in eight steps, while the final synthetic route affords aristopyridinone A in nine steps.  The 2-
pyridone scaffold was successfully achieved through a merged Diels-Alder cycloaddition-
cycloreversion.  Although the syntheses are relatively short, we ran into several complications 
with regards to regioselectivity and desired reactivity.  We were unsuccessful in achieving 
desired regioselectivity in the Diels-Alder cycloaddition despite trying a variety of dieneophiles, 
and faced issues with performing the retro Diels-Alder reaction and with deprotection of the 
pyridone functionality. 
The results from the model system led us to try dieneophiles with reverse electronics 
from propargyl alcohol in the hope that it would reverse the regioselectivity of the Diel-Alder 
reaction.  Ethyl propiolate has opposite electronics than propargyl alcohol, and methyl 
nitroacrylate has differing electronics from both.  Surprisingly, our attempts show that the 
regioselectivity of our intermolecular [4+2] cycloaddition is largely insensitive to electronics of 
the dieneophile (Table 2.1).  Also of note is the differing reaction conditions under which the 
Diels-Alder reaction occurs.  The energy threshold is significantly lower for the cycloaddition of 
the azadiene and nitroacrylate than either of the alkyne-derived dieneophiles.   
40 
 
An unexpected obstacle was the rearrangement of our desired cycloadduct instead of the 
cycloreversion upon activation with Ac2O.  We hypothesize that an asynchronous transition state 
of the retro Diels-Alder reaction allows for elimination of the bridgehead hydrogen in our desired 
regioisomer, which is doubly activated located both #- to the imide and $- to the unsaturated 
ester.  The rate of this elimination appears faster than the [4+2] cycloreversion. Substituting the 
ester for a saturated group at the allylic position in the desired cycloadduct afforded the 
cycloreversion product upon activation. 
Table 2.1 Summary of Diels-Alder regioselectivity studies
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A second complication was problems with the de-protection of the 2-pyridone 
functionality through cleavage of the DMB protecting group.  Reduction at the benzylic position 
of 32, resulting in the loss of the acetate group, was a concern upon our initial attempt at acidic 
deprotection.  Protonation of the acetate group creates a good leaving group and the presence of 
Et3SiH provides a hydride source to capture the cation produced.  However, the major oxidation 
product was not what we expected, nor was the ensuing difficulty with oxidative removal of the 
DMB group.  Although we reverted back to an acidic cleavage strategy, future investigation of 
oxidation products may be worthwhile. 
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Conclusion: 
Outlined in this paper are syntheses of aristopyridinone A and its C-isomer that explore 
the chemistry of the intermolecular Diels-Alder using a diketopiperazine-derived azadiene.  The 
C-isomer of aristopyridinone A was achieved in eight steps and 2.2% total yield.  
Aristopyridinone A will be completed in nine steps from DMB-protedcted diketopiperazine 
starting material.  Our studies showed that the intermolecular Diels-Alder using a DKP-derived 
azadiene does not respond to electronic properties of the dieneophile alone.  Since both syntheses 
were only performed once, optimization of reaction conditions for both routes should be feasible.  
Optimization, along with running the reactions on a larger scale, should improve yields.  Future 
endeavors may also investigate the possibilities of creating other isomers of aristopyridinone A 
via selective extrusion of the other aza bridging function in any of the cycloadducts. Synthesis of 
sufficient quantities of aristopyridinone A and its isomers can be used for biological testing. 
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Experimental Procedures: 
 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame 
or oven-dried glassware with magnetic stirring unless otherwise indicated.  Dicholoromethane 
was distilled from CaH2 prior to use.  All reagents were used as received unless otherwise noted.  
Flash column chromatography was performed using SiliCycle siliaflash P60 silica gel (230-400 
mesh). Microwave reactions were performed in a CEM Discover System Model 908005.  
Melting points were taken using Mel-Temp II device. Analytical thin layer chromatography was 
performed on SiliCycle 60Å glass plates.  Visualization was accomplished with UV light and 
ceric ammonium molybdate followed by heating.  Film infrared spectra were obtained using a 
Digilab FTS 7000 FTIR spectrophotometer. 1H and 13C NMR spectra were obtained on a Agilent 
400/54 ASP spectrometer (400 MHz and 100 MHz, respectively) and are reported in ppm using 
solvent as an internal standard (CDCl3 at 7.26 ppm or CD3OD at 3.34 ppm) or tetramethylsilane 
(0.00 ppm).  Mass spectra data analysis was obtained through positive electrospray ionization 
(w/ NaCl) on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source. 
 
 
 
(Z)-3-benzylidene-1-(3,4-dimethoxybenzyl)-5-methoxy-3,6-dihydropyrazin-2(1H)-one (2): 
To a solution of DMB protected diketopiperazine 1 (375 mg, 1.35 mmol) dissolved in toluene 
(10 mL) and cooled to -78 ºC was added LiHMDS solution (1.5 mL, 1M in THF) dropwise over 
5 minutes.  After allowing 15 minutes for enolization, benzaldehyde (150 "L, 1.48 mmol) was 
added slowly.  The aldol condensation was shown to be complete by TLC after 30 minutes.  The 
reaction was quenched with saturated NH4Cl solution (10 mL) and extracted with EtOAc (3 x 10 
mL).  The organic layers were combined and washed with saturated NaCl solution (15 mL), 
dried with Na2SO4, and concentrated in vacuo.  The resulting residue was dissolved in 
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CHO
N
NDMB
OMe
O
1 2
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dichloromethane (4 mL). To the solution was added Ac2O (255 "L, 2.7 mmol), NEt3 (375 "L, 
2.7 mmol), and DMAP (10 mg, 0.082 mmol).  The reaction was stirred at room temperature 
overnight.  The reaction was quenched with saturated NH4Cl solution (5 mL) and extracted with 
ether (3 x 5 mL).  The organic layers were combined and washed with saturated NaHCO3 
solution (5 mL), washed with saturated NaCl solution (5 mL), dried with Na2SO4, and 
concentrated in vacuo.  The resulting residue was dissolved in DMF (2.5 mL) and toluene (4 
mL).  To the solution was added DBU (300 "L, 2.0 mmol).  The reaction mixture was stirred at 
room temperature overnight. The reaction was quenched with saturated NH4Cl solution (8 mL) 
and extracted with EtOAc (3 x 10 mL).  The organic layers were combined and washed with 
saturated NaCl solution (10 mL), dried with Na2SO4, and concentrated in vacuo.  The resulting 
residue was purified by flash column chromatography on silica gel (0% to 5% methanol in 
CHCl3) to afford exocyclic diene 2 (217 mg, 58% yield) as a yellow orange oil. TLC (60% 
EtOAc in hexanes) Rƒ = 0.53 (CAM/UV); IR (film) cm-1 3055, 2998, 2946, 2836, 2360, 2339, 
1665, 1614, 1559, 1504, 1477, 1442, 1423, 1369, 1288, 1252, 1207, 1157, 1122, 1033, 1005, 
927, 835, 763, 693; 1H NMR (400 MHz, CDCl3) # 8.03-8.01 (2H, d, J = 7.8 Hz), 7.37-7.26 (5H, 
m), 6.48-6.47 (1H, d, J = 2.4 Hz), 6.46-6.45 (1H, d, J = 2.0 Hz), 4.67 (2H, s), 4.09 (2H, s), 3.91 
(3H, s), 3.82 (3H, s), 3.79 (3H, s); 13C NMR (100 MHz, CDCl3) # 160.9, 159.3, 135.8, 131.9, 
131.5, 131.4, 128.4, 128.3, 126.2, 116.6, 104.7, 98.6, 55.7, 54.2, 46.8, 44.3; Exact mass 
calculated for C21H22N2O4Na [M+Na] 389.1472. Found 389.1467. 
 
 
 
(1S,4S)-4-benzyl-2-(3,4-dimethoxybenzyl)-8-(hydroxymethyl)-6-methoxy-2,5-
diazabicyclo[2.2.2]octa-5,7-dien-3-one (3): To a solution of exocyclic azadiene 2 (71.1 mg, 
0.194 mmol) in toluene (2 mL) was added DBU (29 "L, 0.194 mmol) and excess propargyl 
alcohol (1.0 mL).  The reaction mixture was heated to 110 ºC and was found to be complete after 
48 hours by TLC.  The reaction was concentrated in vacuo and the resulting residue was re-
dissolved in CHCl3 (5 mL). The solution was washed with saturated NH4Cl solution (3 mL), 
washed with saturated NaHCO3 solution (3 mL), washed with saturated NaCl solution (5 mL), 
dried with Na2SO4, and concentrated in vacuo.  The resulting residue was purified by flash 
column chromatography on silica gel (40% to 100% EtOAc in hexanes) to afford an inseparable 
mixture of Diels-Alder cycloadducts, desired product 3 and regioisomer 4 (50.2 mg, 61% yield) 
in a ratio of 1:3. TLC (60% EtOAc in hexanes) Rƒ = 0.30 (CAM/UV); IR (film) cm-1 3396, 
3061, 2969, 2838, 2362, 2060, 1954, 1876, 1706, 1576, 1582, 1513, 1430, 1306, 1208, 1145, 
1031, 984, 930, 899, 858, 833, 730, 697; 1H NMR (400 MHz, CDCl3) # 7.63-7.62 (1H, d, J = 7.5 
Hz), 7.52-7.50 (1H, d, J = 8.6 Hz), 7.31-7.20 (10H, m), 7.05-7.03 (1H, d, J = 7.8 Hz), 6.43-6.40 
(4H, m), 6.33 (1H, d, J = 1.9 Hz), 4.64 (1H, s), 4.63-4.60 (1H, d, J = 7.8 Hz), 4.50-4.27 (6H, m), 
4.21-4.01 (2H, m), 3.87 (1H, s), 3.82 (1H, s), 3.78-3.69 (18H, m), 3.52-3.45 (4H, m); 13C NMR 
(100 MHz, CDCl3) # 174.7, 174.2, 172.6, 172.3, 160.8, 160.7, 158.2, 155.0, 146.2, 138.3, 137.9, 
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134.0, 131.3, 131.2, 130.8, 130.7, 127.8, 127.7, 127.1, 126.3, 126.1, 116.7, 116.4, 104.2, 104.0, 
98.4, 98.3, 77.3, 73.6, 72.0, 60.9, 60.6, 58.3, 56.3, 55.32, 55.3, 55.1, 43.9, 43.2, 37.6, 35.1; Exact 
mass calculated for C24H26N2O5Na [M+Na] 445.1734. Found 445.1734. 
 
 
 
 
(1S,4S)-1-benzyl-5-(3,4-dimethoxybenzyl)-7-(hydroxymethyl)-2,5-diazabicyclo[2.2.2]oct-7-
ene-3,6-dione (5): To a solution of cycloadducts 3 and 4 (77.2 mg, 0.198 mmol) in acetic acid 
(3.0 mL) was added potassium iodide (98.53 mg, 0.594 mmol).  The reaction mixture was heated 
to 110 ºC and was found to be complete after 2 hours by TLC.  It was diluted and neutralized 
with saturated NaHCO3 solution (10 mL) and extracted with EtOAc (3 x 6 mL).  The organic 
layers were combined and washed with saturated NaHCO3 solution (6 mL), washed with 
saturated NaCl solution (6 mL), dried with Na2SO4, and concentrated in vacuo. The resulting 
residue was purified by flash column chromatography on silica gel (40% to 100% EtOAc in 
hexanes with 10% CHCl3) to afford desired product 5 and regioisomer 6 (13.4 mg and 31.7 mg, 
respectively, 61% total yield) as yellow oils.  Product 5: TLC (60% EtOAc in hexanes) Rƒ = 
0.14 (CAM/UV); IR (film) cm-1 3394, 3249, 3068, 3011, 2933, 2842, 1746, 1705, 1613, 1588, 
1509, 1454, 1294, 1211, 1158, 1037, 967, 921, 839, 754; Exact mass calculated for 
C23H24N2O5Na [M+Na] 431.1577. Found 431.1581. 
 
Product (6): TLC (60% EtOAc in hexanes) Rƒ = 0.22 (CAM/UV); IR (film) cm-1 3327, 3071, 
1008, 2935, 2838, 2362, 2075, 1966, 1704, 1673, 1610, 1586, 1454, 1412, 1333, 1294, 1212, 
1140, 1038, 968, 923, 835, 751, 701; 1H NMR # 7.36-7.27 (4H, m), 7.10-7.08 (1H, d, J = 7.8 
Hz), 6.42 (1H, s), 6.40-6.39 (1H, d, J = 2.3 Hz), 6.37-6.36 (1H, d, J = 2.0 Hz), 6.30 (1H, s), 4.66-
4.62 (1H, d, J = 14.5 Hz), 4.40 (1H, s), 4.4.36-4.35 (1H, d, J = 2.7 Hz), 3.97-3.93 (1H, dd, J = 
11.8 Hz and 3.1 Hz), 3.86-3.81 (2H, dd, J = 9.8 Hz and 4.7 Hz), 3.77 (3H, s), 3.76 (3H, s), 3.46-
3.42 (1H, d, J = 14.9 Hz), 3.39-3.35 (1H, d, J = 14.8 Hz); 13C (100 MHz, CDCl3) # 172.2, 170.8, 
161.3, 158.9, 150.2, 134.9, 131.8, 131.5, 130.4, 129.2, 127.7, 116.4, 104.6, 98.7, 77.6, 63.7, 62.9, 
61.1, 55.6, 55.5, 44.0, 35.4; Exact mass calculated for C23H24N2O5Na [M+Na] 431.1577. Found 
431.1581. 
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(3-benzyl-1-(3,4-dimethoxybenzyl)-2-oxo-1,2-dihydropyridin-4-yl)methyl acetate (7): To a 
solution of cycloadduct 5 (13.5 mg, 0.036 mmol) in Ac2O (1.0 mL) was added pyridine (1.0 
mL).  The reaction mixture was heated to 110 ºC and allowed to react for 3.5 days.  The reaction 
was concentrated in vacuo, washed three times with CHCl3, and again concentrated in vacuo.  
The resulting residue was purified by flash column chromatography on silica gel (20% to 100% 
EtOAc in hexanes) to afford DMB-protected pyridone 7 (8.0 mg, 67% yield).  TLC (60% EtOAc 
in hexanes) Rƒ = 0.72 (CAM/UV); IR (film) cm-1 3084, 3064, 3026, 3001, 2960, 2926, 2857, 
1739, 1700, 1695, 1653, 1613, 1589, 1558, 1507, 1495, 1464, 1457, 1436, 1419, 1375, 1363, 
1288, 1264, 1225, 1210, 1158, 1138, 1122, 1031, 964, 939, 919, 831, 786, 757, 733, 701, 667; 
Exact mass calculated for C24H25NO5Na [M+Na] 430.1625. Found 430.1625 
 
 
 
(5-benzyl-1-(3,4-dimethoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)methyl acetate (8): To a 
solution of cycloadduct 6 (30.0 mg, 0.0798 mmol) in Ac2O (2.0 mL) was added pyridine (2.0 
mL).  The reaction mixture was heated to 110 ºC and allowed to react for 2.5 days.  The reaction 
was concentrated in vacuo, washed three times with CHCl3, and again concentrated in vacuo.  
The resulting residue was purified by flash column chromatography on silica gel (20% to 100% 
EtOAc in hexanes) to afford DMB-protected pyridone 8 (25.8 mg, 97% yield).  TLC (60% 
EtOAc in hexanes) Rƒ = 0.78 (CAM/UV); IR (film) cm-1 3082, 3060, 3026, 3002, 2955, 2934, 
2836, 2739, 1734, 1717, 1700, 1695, 1684, 1671, 1661, 1635, 1616, 1613, 1589, 1576, 1569, 
1558, 1507, 1495, 1464, 1436, 1419, 1378, 1362, 1289, 1265, 1226, 1210, 1158, 1138, 1121, 
1075, 1030, 948, 941, 919, 872, 831, 787, 757, 734, 701, 667; 1H NMR (400 MHz, CDCl3) # 
7.41-7.40 (1H, d, J = 2.7 Hz), 7.38 (1H, m), 7.33-7.20 (5H, m), 6.95 (1H, m), 6.48-6.47 (1H, d, J 
= 2.4 Hz), 6.45 (1 H, s), 5.05 (2H, s), 4.72 (2H, s), 3.86 (2H, s), 3.82 (3H, s), 3.80 (3H, s), 2.02 
(3H, s); 13C NMR (100 MHz, CDCl3) # 171.0, 162.4, 161.2, 159.0, 139.6, 137.5, 136.7, 133.3, 
132.8, 129.6, 128.7, 126.5, 116.7, 113.0, 104.5, 98.7, 63.9, 55.6, 55.5, 48.0, 36.8, 21.2; Exact 
mass calculated for C24H25NO5Na [M+Na] 430.1625. Found 430.1628. 
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1-(4-(2,4-dimethoxybenzyl)-6-methoxy-3-oxo-2,3,4,5-tetrahydropyrazin-2-yl)-2-(4-
methoxyphenyl)ethyl acetate (10): To a solution of DMB-diketopiperazine 1 (338 mg, 1.21 
mmol) dissolved in THF (5 mL) was added LiHMDS solution (1.28 mL, 1M in THF) at -78°C 
dropwise over 5 minutes. After allowing 15 minutes for enolization, a solution of aldehyde 9 
(158.5 mg, 1.33 mmol in 2 mL THF) was added slowly. The reaction proceeded for 30 minutes 
at -78°C. To the solution, pyridine (152 µL, 1.57 mmol) and acetic anhydride (126 µL, 1.57 
mmol) were added. The reaction was allowed to come to room temperature overnight. The 
solution was concentrated in vacuo and redissolved in dichloromethane (10 mL). This was 
washed with 0.1M HCl (10 mL) and the aqueous layer was extracted with dichloromethane 
(3x10 mL). The combined organic layers were washed with saturated NaHCO3 solution (40 mL), 
saturated NaCl solution (40 mL), dried with anhydrous Na2SO4, filtered and concentrated in 
vacuo. The product was purified by flash chromatography on silica gel (10% to 60% EtOAc in 
hexanes with added constant 5% chloroform) to afford the DMB-Diketopiperazine Acetate 3 
(390 mg, 69% yield) as an inseparable mixture of diastereomers. TLC (60% EtOAc in hexanes) 
Rƒ = 0.76 (CAM/UV); IR (film) cm-1 3054, 2998, 2948, 2837, 2358, 2336, 2060, 1741, 1701, 
1652, 1615, 1587, 1558, 1515, 1489, 1465, 1457, 1373, 1320, 1296, 1248, 1211, 1179, 1158, 
1131, 1034, 938, 859, 833, 788, 735; 1H NMR (400 MHz, CDCl3) $ 7.30-7.19 (6H, m), 6.94-
6.81 (4H, m), 6.47-6.41 (4H, m), 5.54-5.50 (1H, m), 5.37-5.33 (1H, m), 4.82-4.75 (4H, d, J = 
14.9 Hz), 4.44-4.40 (2H, d, J = 14.4 Hz), 4.28-4.25 (2H, d, J = 14.5 Hz), 4.09-4.08 (1H, d, J = 
2.0 Hz), 3.89-3.88 (1H, d, J = 2.0 Hz), 3.87-3.65 (24H, m), 3.17-3.11 (1H, m), 3.04-2.91 (3H, 
m), 1.87 (3H, s), 1.70 (3H, s); 13C NMR (100 MHz, CDCl3) $ 170.1, 169.7, 167.0, 165.9, 160.9, 
160.0, 159.1, 158.9, 158.8, 158.6, 158.5, 131.9, 131.2, 131.1, 131.0, 129.4, 129.2, 116.8, 116.3, 
114.1, 114.0, 104.8, 104.7, 98.5, 78.0, 77.7, 77.1, 60.6, 59.8, 55.6, 55.5, 55.4, 53.4, 53.3, 46.1, 
46.0, 43.5, 43.2, 36.5, 35.8, 21.2, 21.1; Exact mass calculated for C25H30N2O7Na [M+Na] 
493.1945. Found 493.1941. 
 
 
 
1-(2,4-dimethoxybenzyl)-5-methoxy-3-(4-methoxyphenethyl)pyrazin-2(1H)-one (11): To a 
solution of DMB-DKP 10 (390 mg, 0.83 mmol) in toluene (5 mL) was added DBU (0.136 mL, 
0.911 mmol). The reaction mixture was heated to 110 ºC and stirred with a magnetic stirrer. The 
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reaction was tracked by TLC and appeared to be complete after 16 hours. The reaction was 
quenched with saturated aqueous NH4Cl solution, and the aqueous layer was extracted with 
EtOAc (3x10 mL) The combined organic layers were washed with saturated NaHCO3 solution, 
saturated NaCl solution, dried with Na2SO4, and concentrated in vacuo. This afforded azadiene 
11 as a brown oil (354 mg) with a small amount of another highly UV active product, 
presumably the exocyclic azadiene. Azadiene 11 is not stable to silica gel and was used in 
subsequent reactions without purification. TLC (60% EtOAc in hexanes) Rƒ = 0.60 (CAM / 
UV). IR (film) cm-1 3083, 3001, 2940, 2842, 2597, 2546, 2484, 2425, 2238, 2146, 2058, 1876, 
1698, 1672, 1580, 1509, 1442, 1360, 1291, 1241, 1206, 1170, 1121, 1076, 1034, 931, 834, 749; 
1H NMR (400 MHz, CDCl3) $ 7.34-7.32 (1H, d, J = 9.0 Hz), 7.19-7.17 (2H, d, J = 8.6 Hz), 6.81-
6.78 (2H, d, J = 8.6 Hz), 6.75 (1H, s), 6.45 (2H, m), 4.99 (2H, s), 3.79 (3H, s) 3.76 (3H, s), 3.74 
(3H, s), 3.73 (3H, s), 3.14-3.10 (2H, t, J = 7.6 Hz), 3.02-2.98 (2H, t, J = 7.6 Hz) ; 13C NMR (100 
MHz, CDCl3) $ 161.2, 158.6, 157.7, 156.4, 154.5,  146.6, 133.6, 132.4, 129.4, 129.3, 115.3, 
113.7, 113.6, 109.7, 104.4, 98.4, 77.4, 55.2, 55.0, 47.5, 35.0, 31.2; Exact mass calculated for 
C23H26N2O5Na [M+Na] 433.1734. Found 433.1734. 
 
 
 
(1S,4S)-ethyl-5-(2,4-dimethoxybenzyl)-3-methoxy-1-(4-methoxyphenethyl)-6-oxo-2,5-
diazabicyclo[2.2.2]octa-2,7-diene-7-carboxylate (12): To a solution of azadiene 11 (320 mg, 
0.78 mmol) in toluene (2.5 mL) was added excess ethyl propiolate (2.5 mL). The reaction was 
heated to 110°C for 18 hours, when the reaction was complete as judged by TLC. The reaction 
was concentrated in vacuo and purified by flash column chromatography on silica gel (20% to 
80% EtOAc in hexanes) to afford a largely inseparable mixture of Diels-Alder cycloadducts, 
desired product 12 and regioisomer 13 (250 mg, 63%  combined yield) in a ratio of 1:2. TLC 
(60% EtOAc in hexanes) Rƒ = 0.72 (UV, CAM); IR (film) cm-1 2994, 2944, 2909, 1836, 2360, 
1717, 1686, 1685, 1646, 1612, 1587, 1512, 1456, 1438, 1419, 1368, 1328, 1291, 1246, 1210, 
1175, 1158, 1124, 1034, 936, 833, 733; 1H NMR (400 MHz, CDCl3) $ 7.30-7.29 (1H, d, J = 2.0 
Hz), 7.24 (1H, s), 7.19 (1H, s), 7.15-7.14 (1H, d, J = 5.5 Hz), 7.01-6.96 (2H, m), 6.82-6.78 (4H, 
m), 6.38 (2H, s), 6.37-6.34 (4H, m), 5.09-5.08 (1H, d, J = 2.0 Hz), 4.64-4.62 (1H, d, J = 5.8 Hz), 
4.47-4.39 (2H, m), 4.32-4.31 (1H, d, J = 4.7 Hz), 4.29-4.28 (1H, d, J =4.6 Hz), 4.16-4.10 (2H, q, 
J = 7.1 Hz), 4.09-4.00 (2H, m), 3.76-3.67 (24H, m), 3.00-2.40 (8H, m), 1.25-1.17 (6H, m); 13C 
NMR (100 MHz, CDCl3) $ 175.0, 173.8, 171.2, 163.8, 162.1, 160.91, 160.89, 158.6, 158.5, 
157.7, 157.5, 150.2, 145.7, 140.8, 138.0, 135.5, 134.6, 131.5, 129.5, 129.4, 116.2, 116.0, 113.7, 
113.6, 104.1, 104.0, 98.4, 98.3, 77.3, 73.4, 73.0, 61.1, 61.0, 56.9, 56.3, 55.6, 55.4, 55.3, 55.2, 
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55.1, 44.0, 43.9, 34.1, 32.4, 30.4, 29.5, 14.1, 14.0; Exact mass calculated for C28H32N2O7Na 
[M+Na] 531.2102. Found 531.2100. 
 
 
 
(1S,4S)-ethyl-5-(2,4-dimethoxybenzyl)-1-(4-methoxyphenethyl)-3,6-dioxo-2,5-
diazabicyclo[2.2.2]oct-7-ene-7-carboxylate (14): To a solution of cycloadducts 12 and 13 (509 
mg, 0.90 mmol) in AcOH (5 mL) was added potassium iodide (445 mg, 2.68 mmol). The 
reaction proceeded at 100°C for approximately 2.5 hours. It was diluted and neutralized with 30 
mL saturated sodium bicarbonate solution. This was extracted with EtOAc (3x20 mL). The 
organic layers were combined and washed with saturated NaHCO3 solution (20 mL) and 10% 
NaS2O3 solution (10 mL). It was then washed with saturated NaCl solution and dried with 
Na2SO4. The product was then concentrated in vacuo. The product was then purified by flash 
column chromatography on silica gel (20% to 100% EtOAc in hexanes with added constant 5% 
CHCl3) resulting in a largely inseparable mixture of demethylated products 14 and 15 (254 mg, 
57% yield). TLC (60% EtOAc in hexanes) Rƒ = 0.57 (CAM/UV); IR (film) cm-1 3197, 2997, 
2958, 2935, 2837, 2063, 1717, 1701, 1686, 1612, 1587, 1512, 1465, 1438, 1404, 1368, 1293, 
1266, 1246, 1209, 1158, 1140, 1116, 1096, 1036, 936, 735; 1H NMR (400 MHz, CDCl3) $ 7.37-
7.36 (1H, d, J = 5.9 Hz), 7.29-7.28 (1H, d, J = 1.9 Hz), 7.24-7.19 (2H, m), 7.10-7.06 (2H, m), 
6.96-6.94 (2H, d, J = 7.4 Hz), 6.88-6.85 (4H, m), 6.43-6.37 (4H, m), 4.88-4.87 (1H, d, J = 2.0 
Hz), 4.68-4.64 (1H, d, J = 14.1 Hz), 4.61-4.57 (1H, d, J = 14.6 Hz), 4.49-4.47 (2H, m), 4.42-4.35 
(2H, m), 4.23-4.17 (2H, q, J = 6.0 Hz), 4.15-4.06 (3H, m), 3.81-3.75 (18H, m), 2.89-2.81 (4H, 
m), 2.78-2.59 (2H, m), 2.45-2.33 (2H, m), 1.28-1.25 (3H, t, J = 7.0 Hz), 1.23-1.20 (3H, t, J = 7.0 
Hz); 13C NMR (100 MHz, CDCl3) $ 172.3, 171.6, 169.4, 169.3, 162.8, 161.8, 161.3, 158.8, 
158.3, 158.1, 146.2, 140.9, 133.8, 133.0, 131.8, 129.7, 129.6, 115.8, 115.7, 114.2, 114.0, 104.4, 
104.3, 98.7, 98.6, 98.5, 77.6, 66.0, 64.5, 61.6, 61.5, 61.2, 61.0, 55.5, 55.4, 55.3, 55.2, 44.8, 44.6, 
31.6, 30.0, 29.9, 29.0, 14.3, 14.2, 14.1; Exact mass calculated for C27H30N2O7Na [M+Na] 
517.1945. Found 517.1945. 
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ethyl-1-(2,4-dimethoxybenzyl)-3-(4-methoxyphenethyl)-2-oxo-1,2-dihydropyridine-4-
carboxylate (16): To a solution of mixed regioisomers 14 and 15 (134 mg, 0.27 mmol) in Ac2O 
(2.5 mL) was added pyridine (0.066 mL, 0.81 mmol). The reaction mixture was heated to 140 ºC 
and allowed to react for 48 hours. The reaction was concentrated in vacuo after adding toluene 
and then CHCl3. The resulting residue was purified by flash column chromatography on silica 
gel (10% to 60% EtOAc in hexanes with added constant 10% CHCl3) to afford product 16 and 
another product 17 (78 mg and 18 mg, respectively). Product 16: TLC (60% EtOAc in hexanes) 
Rƒ = 0.74 (CAM/UV); IR (film) cm-1 2958, 2934, 2836, 1889, 1868, 1844, 1783, 1717, 1652, 
1615, 1588, 1559, 1512, 1456, 1437, 1368, 1298, 1245, 1210, 1178, 1158, 1131, 1033, 940, 822, 
764; 1H NMR (400 MHz, CDCl3) $ 8.31 (1H, s), 7.61 (1H, s), 7.39-7.38 (1H, d, J = 7.8 Hz), 
7.14-7.12 (2H, d, J = 8.6 Hz), 6.82-6.80 (2H, d, J = 8.2 Hz), 6.49-6.48 (1H, d, J = 2.3 Hz), 6.46 
(1H, s), 5.09 (2H, s), 4.31-4.26 (2H, q, J = 7.2 Hz), 3.84 (3H, s), 3.80 (3H, s), 3.78 (3H, s), 2.85-
2.78 (4H, m), 1.36-1.32 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) $ 164.8, 162.7, 161.1. 
158.7, 157.7, 141.4, 134.8, 133.7, 132.4, 131.5, 129.3, 116.0, 113.6, 108.6, 104.2, 98.5, 60.6, 
55.2, 48.4, 33.4, 33.1, 14.3; Exact mass calculated for C26H29NO6Na [M+Na] 474.1887. Found 
474.1887. 
 
Product 17: TLC (60% EtOAc in hexanes) Rƒ = 0.55 (CAM/UV); IR (film) cm-1 2957, 2925, 
2854, 1942, 1919, 1888, 1868, 1843, 1825, 1791, 1771, 1733, 1717, 1700, 1695, 1684, 1675, 
1653, 1616, 1576, 1558, 1457, 1436, 1373, 1245, 1209, 1176, 1158, 1032, 826; 1H NMR (400 
MHz, CDCl3) $ 8.01 (1H, s), 7.17-7.15 (3H, m), 6.83-6.81 (2H, d, J = 8.6 Hz), 6.61 (1H, s), 
6.42-6.40 (1H, d, J = 8.2 Hz), 6.38 (1H, s), 5.42 (2H, s), 4.33-4.28 (2H, q, J = 7.2 Hz), 3.79 (3H, 
s), 3.77 (3H, s), 3.70 (3H, s), 3.19-3.15 (2H, t, J = 8.0 Hz), 2.81-2.78 (2H, t, J = 7.8 Hz), 2.50 
(3H, s), 2.30 (3H, s), 1.37-1.34 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) $ 172.1, 165.3, 
162.7, 161.4, 160.9, 158.5, 157.8, 139.2, 138.9, 135.6, 133.7, 132.1, 129.5, 116.5, 113.7, 106.5, 
104.0, 98.5, 62.0, 55.4, 55.2, 44.0, 33.8, 31.1, 25.4, 24.9, 14.2; Exact mass calculated for 
C29H33N2O6Na [M+Na] 559.2056. Found 559.2049. 
 
HN
NO
CO2Et
O
OMe
HN
NOO
OMe
CO2Et
MeO
OMe
MeO
OMe
+
14 15
Ac2O, pyridine
140 ºC
NO N
H
O O
MeO
MeO
OMe
+
N
OMeO OMe
OMe
OO
O O
17
16
52 
 
 
 
ethyl 3-(4-methoxyphenethyl)-2-oxo-1,2-dihydropyridine-4-carboxylate (18): To a solution 
of product 16 (25 mg, 0.055 mmol) in CH2Cl2 (0.5 mL) was added trifluoracetic acid (0.25 mL) 
and triethylsilane (0.25mL).  The reaction mixture was heated in the microwave (temperature 
mode = 130 ºC, 30 min). The reaction mixture was concentrated in vacuo and purified by flash 
column chromatography on silica gel (1% to 10% methanol in CHCl3) to afford pyridone 18 
(16.5 mg, 99% yield) as a yellow solid. mp 86-88ºC; TLC (5% methanol in CHCl3) Rƒ = 0.48 
(UV, CAM); IR (film) cm-1 2927, 2855, 2835, 1868, 1771, 1733, 1717, 1700, 1695, 1652, 1616, 
1576, 1539, 1465, 1436, 1368, 1300, 1244, 1209, 1177, 1130, 1108, 1094, 1036, 822; 1H NMR 
(400 MHz, CDCl3) $ 12.96 (1H, s), 8.15-8.14 (1H, d, J = 2.3 Hz), 7.79-7.78 (1H, d, J = 2.3 Hz), 
7.16-7.14 (2H, d, J = 8.6 Hz), 6.85-6.82 (2H, d, J = 8.6 Hz), 4.34-4.31 (2H, q, J = 7.0 Hz), 3.79 
(3H, s), 2.90-2.83 (4H, m), 1.37-1.34 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) $ 165.3, 
164.5, 157.9, 137.5, 137.2, 133.4, 121.9, 129.4, 113.8, 111.0, 61.0, 55.2, 33.3, 32.3, 14.3; Exact 
mass calculated for C17H19NO4Na [M+Na] 324.1206. Found 324.1206. 
 
 
 
4-(hydroxymethyl)-3-(4-methoxyphenethyl)pyridin-2(1H)-one (19): To a solution of LiAlH4 
(8.5 mg, 0.21 mmol) in THF (0.250 mL) at 0 ºC was added a solution of pyridone 18 (21 mg, 
0.07 mmol) in THF (0.750 mL).  The reaction was stirred and allowed to slowly come to room 
temperature.  The reaction was tracked by TLC and found to be complete after 4 hours.  The 
reaction was quenched with 1.0 M HCl (5 mL) and extracted with EtOAc (3 x 8 mL).  The 
organic layers were combined and washed with saturated NaCl solution, dried with Na2SO4, and 
concentrated in vacuo. The resulting residue was purified by flash column chromatography on 
silica gel (25% to 100% EtOAc in hexanes) to afford pyridone 19 (7.6 mg, 42% yield) as a pale 
yellow solid. mp 143-144ºC; TLC (100% EtOAc) Rƒ = 0.27 (CAM/UV). IR (film) cm-1 3198, 
3007, 2929, 2835, 2360, 2337, 1695, 1653, 1622, 1511, 1456, 1296, 1244, 1207, 1180, 1106, 
1032, 1000, 818, 735, 540; 1H NMR (400 MHz, CD3OD ) $ 7.34-7.33 (1H, d, J = 2.4 Hz), 7.24-
7.23 (1H, d, J = 2.4 Hz), 7.11-7.09 (2H, d, J = 8.6 Hz), 6.81-6.79 (2H, d, J = 8.6 Hz), 4.32 (2H, 
s), 3.75 (3H, s), 2.82-2.75 (4H, m); 13C NMR (100 MHz, CD3OD) $ 165.0, 159.6, 141.2, 135.1, 
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133.6, 131.2, 130.6, 122.2, 114.9, 61.9, 55.8, 34.9, 34.0; Exact mass calculated for C15H17NO3Na 
[M+Na] 282.1101. Found 282.1101. 
 
 
 
 
ethyl 3-(4-hydroxyphenethyl)-2-oxo-1,2-dihydropyridine-4-carboxylate (20): To a solution 
of pyridone 18 (17.0 mg, 0.056 mmol) in CH2Cl2 (0.5 mL) cooled to -78 ºC was added BBr3 
(0.226 mL, 0.226 mmol) dropwise.  The reaction mixture was allowed to warm to room 
temperature and was stirred for 2.5 hours.  The reaction was diluted and quenched with saturated 
sodium bicarbonate solution (5 mL).  It was then extracted with EtOAc (3 x 5mL).  The organic 
layers were combined and washed with saturated NaCl solution, dried with Na2SO4, and 
concentrated in vacuo.  The resulting residue was purified by flash column chromatography on 
silica gel (15% to 100% EtOAc in hexanes) to afford pyridone 20 (15.0 mg, 93% yield) as a pale 
yellow solid. mp 166-168ºC; TLC (60% EtOAc in hexanes) Rƒ = 0.26 (UV, CAM); IR (film) 
cm-1 3357, 2923, 2853, 1716, 1696, 1653, 1636, 1515, 1457, 1430, 1367, 1294, 1242, 1169, 
1135, 1022, 1094, 825, 788, 722, 695, 639, 540; 1H NMR (400 MHz, CD3OD) $ 8.01-8.00 (1H, 
d, J = 2,7 Hz), 7.68-7.67 (1H, d, J = 2.2 Hz), 7.01-6.99 (2H, d, J = 8.6 Hz), 6.68-6.66 (2H, d, J = 
8.6 Hz), 4.31-4.25 (2H, q, J = 7.0 Hz), 2.78-2.75 (4H, m), 1.35-1.31 (3H, t, J = 7.0 Hz); 13C 
NMR (100 MHz, CD3OD) $ 166.1, 165.5, 156.7, 138.7, 138.6, 133.6, 133.3, 120.6, 116.2, 111.9, 
62.2, 34.6, 33.9, 14.7. 
 
 
 
5-(hydroxymethyl)-3-(4-hydroxyphenethyl)pyridin-2(1H)-one (21): To a solution of LiAlH4 
(6.6 mg, 0.17 mmol) in THF (0.250 mL) at 0 ºC was added a solution of pyridone 20 (12.4 mg, 
0.043 mmol) in THF (0.750 mL).  The reaction was stirred and allowed to slowly come to room 
temperature.  The reaction was tracked by TLC and found to be complete after 2.5 hours.  The 
reaction was quenched with 1.0 M HCl (5 mL) and extracted with EtOAc (4 x 8 mL).  The 
organic layers were combined and washed with saturated NaCl solution, dried with Na2SO4, and 
concentrated in vacuo. The resulting residue was purified by flash column chromatography on 
silica gel (0% to 5% methanol in EtOAc) to afford iso-aristopyridinone 21 (1.6 mg, 15% yield) 
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as an off-white solid. mp >260 ºC; TLC (100% EtOAc) Rƒ = 0.10 (CAM/UV). IR (film) cm-1 
2954, 2923, 2854, 2360, 2340, 1716, 1700, 1683, 1635, 1653, 1558, 1539, 1506, 1457, 1260, 
1099, 1020, 802, 680, 649, 668; 1H NMR (400 MHz, CD3OD ) $ 7.34-7.33 (1H, d, J = 2.3 Hz), 
7.24-7.23 (1H, d, J = 2.4 Hz), 7.02-7.00 (2H, d, J = 8.6 Hz), 6.68-6.66 (2H, d, J = 8.6 Hz), 4.32 
(2H, s), 2.78-2.75 (4H, m); 13C NMR (100 MHz, CD3OD) $ 165.0, 156.7, 141.2, 133.9, 133.7, 
131.2, 122.2, 116.2, 62.0, 34.9, 34.1. 
 
 
 
 
methyl-5-(3,4-dimethoxybenzyl)-3-methoxy-1-(4-methoxyphenethyl)-8-nitro-6-oxo-2,5-
diazabicyclo[2.2.2]oct-2-ene-7-carboxylate (22): To a solution of azadiene 11 (452 mg, 1.10 
mmol) in toluene (5 mL) cooled to 0 ºC was added a solution of nitroacrylate (131 mg, 1.0 
mmol) in toluene (3 mL).  The reaction was stirred and allowed to come to room temperature 
overnight.  The reaction mixture was concentrated in vacuo.  The resulting residue was purified 
by flash column chromatography on silica gel (10% to 100% EtOAc in hexanes) to afford 
desired cycloadduct 22 and regioisomer 23 (335.8 mg total, 56% total yield) as yellow oils.  
Product 22: TLC (40% EtOAc in hexanes) Rƒ = 0.33 (CAM/UV); IR (film) cm-1 3004, 2951, 
2836, 2359, 2342, 1741, 1694, 1648, 1612, 1588, 1557, 1512, 1456, 1439, 1419, 1371, 1333, 
1299, 1267, 1246, 1209, 1175, 1159, 1125, 1034, 980, 960, 932, 915, 832, 755, 667; 1H NMR 
(400 MHz, CDCl3) # 7.28-7.27 (1H, d, J = 9.0 Hz), 7.21-7.19 (2H, d, J =8.6 Hz), 6.84-6.82 (2H, 
d, J = 8.6 Hz), 6.48-6.46 (2H, m), 5.04-5.02 (1H, dd, J = 3.2 Hz and 4.7 Hz), 4.82-4.81 (1H, d, J 
= 3.1 Hz), 4.60-4.57 (1H, d, J = 14.0 Hz), 4.47-4.44 (1H, d, J = 14.0 Hz), 3.87 (3H, s), 3.80-3.79 
(9H, m), 3.64 (3H, s), 3.29-3.28 (1H, d, J = 5.1 Hz), 2.93-2.87 (2H, m), 2.27-2.24 (1H, m), 2.02-
1.97 (1H, m); 13C NMR (100 MHz, CDCl3) # 169.6, 169.4, 169.0, 161.1, 158.5, 157.7, 134.6, 
132.5, 129.4, 115.8, 113.7, 104.5, 98.4, 84.5, 67.1, 55.5, 55.4, 55.3, 55.2, 54.8, 52.9, 51.1, 43.9, 
34.6, 29.1. 
 
Product 23: TLC (40% EtOAc in hexanes) Rƒ = 0.22 (CAM/UV); IR (film) cm-1 3005, 2952, 
2914, 2837, 2359, 2334, 1743, 1694, 1643, 1612, 1588, 1557, 1512, 1457, 1438, 1419, 1362, 
1298, 1267, 1246, 1209, 1178, 1158, 1125, 1033, 976, 957, 919, 892, 830, 754, 667; 1H NMR 
(400 MHz, CDCl3) # 7.30-7.28 (1H, d, J = 7.8 Hz), 7.20-7.18 (2H, d, J = 8.6 Hz), 6.83-6.81 (2H, 
d, J = 8.6 Hz), 6.48-6.46 (2H, m), 4.98-4.97 (1H, d, J = 4.7 Hz), 4.68-4.65 (1H, d, J = 14.5 Hz), 
4.61-4.60 (1H, d, J = 2.7 Hz), 4.52-4.49 (1H, d, J = 14.1 Hz), 3.84 (3H, s), 3.80-3.77 (9H, m), 
3.73 (3H, s), 3.41-3.39 (1H, dd, J = 1.9 Hz and 2.8 Hz), 2.95-2.87 (2H, m), 2.35-2.27 (1H, m), 
2.04-1.97 (1H, m); 13C NMR (100 MHz, CDCl3) # 172.1, 168.4, 168.3, 161.1, 158.5, 157.7, 
134.2, 132.5, 129.5, 115.9, 113.7, 104.3, 98.4, 87.0, 67.3, 55.4, 55.3, 55.2, 54.9, 54.8, 53.2, 49.5, 
43.8, 33.2, 28.8. 
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methyl-(1S,4S)-5-(3,4-dimethoxybenzyl)-3-methoxy-1-(4-methoxyphenethyl)-6-oxo-2,5-
diazabicyclo[2.2.2]octa-2,7-diene-7-carboxylate (24): To a solution of cycloadduct 22 (115 
mg, 0.213 mmol) in toluene (3 mL) was added DBU (0.054 mL, 0.361 mmol).  The reaction was 
stirred at room temperature overnight.  The reaction mixture was quenched with 0.1 M HCl (5 
mL) and extracted with EtOAc (3 x 8 mL).  The organic layers were combined and washed with 
saturated NaHCO3 solution (5 mL), washed with saturated NaCl solution (5 mL), dried with 
Na2SO4, and concentrated in vacuo.  The resulting residue was purified by flash column 
chromatography on silica gel (10% to 60% EtOAc in hexanes) to afford product 24 (47 mg, 45% 
yield) as a yellow oil.  TLC (40% EtOAc in hexanes) Rƒ = 0.30 (CAM/UV); IR (film) cm-1 
2999, 2947, 2835, 2058, 1725, 1688, 1650, 1612, 1588, 1512, 1456, 1438, 1417, 1331, 1292, 
1266, 1245, 1210, 1171, 1159, 1112, 1090, 1036, 965, 936, 833, 791, 734, 702, 588, 521; 1H 
NMR (400 MHz, CDCl3) # 7.29-7.27 (2H, d, J = 8.6 Hz), 7.21-7.20 (1H, d, J = 5.8 Hz), 7.06-
7.03 (1H, d, J = 8.6 Hz), 6.86-6.83 (2H, d, J = 8.7 Hz), 6.48-6.41 (2H, m), 5.00 (1H, s), 4.69-4.68 
(1H, d, J = 5.5 Hz), 4.47-4.43 (1H, d, J = 14.5 Hz), 4.36-4.32 (1H, d, J = 14.5 Hz), 3.83-3.71 
(15H, m), 3.12-2.97 (2H, m), 2.85-2.66 (2H, m); 13C NMR (100 MHz, CDCl3) # 173.8, 171.8, 
164.2, 160.9, 158.5, 145.4, 141.2, 135.5, 131.5, 129.5, 116.2, 113.7, 113.6, 104.2, 98.4, 73.3, 
56.3, 55.5., 55.4, 55.3, 55.2, 55.1, 44.0, 32.6, 30.1. 
 
 
 
methyl-(1S,4S)-2-(3,4-dimethoxybenzyl)-6-methoxy-4-(4-methoxyphenethyl)-3-oxo-2,5-
diazabicyclo[2.2.2]octa-5,7-diene-7-carboxylate (25): To a solution of cycloadduct 23(50 mg, 
0.092 mmol) in toluene (1.5 mL) was added DBU (0.023 mL, 0.157 mmol).  The reaction was 
stirred at room temperature overnight.  The reaction mixture was quenched with 0.1 M HCl (3 
mL) and extracted with EtOAc (3 x 5 mL).  The organic layers were combined and washed with 
saturated NaHCO3 solution (5 mL), washed with saturated NaCl solution (5 mL), dried with 
Na2SO4, and concentrated in vacuo to afford product 25 (44.7 mg, 99% yield) as a yellow oil.  
TLC (40% EtOAc in hexanes) Rƒ = 0.28 (CAM/UV); IR (film) cm-1 3000, 2949, 2836, 2359, 
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2342, 1770, 1718, 1688, 1646, 1614, 1587, 1558, 1539, 1512, 1457, 1437, 1418, 1360, 1331, 
1291, 1267, 1245, 1209, 1180, 1158, 1078, 1035, 993, 933, 887, 831, 789, 754, 731, 667; 1H 
NMR (400 MHz, CDCl3) # 7.38-7.37 (1H, d, J = 2.0 Hz), 7.26-7.23 (1H, d, J = 9.0 Hz), 7.04-
7.012 (2H, d, J = 8.6 Hz), 6.86-6.84 (2H, d, J = 8.6 Hz), 6.41-6.39 (2H, m), 5.12-5.11 (1H, d, J = 
1.6 Hz), 4.51-4.48 (1H, d, J = 14.1 Hz), 4.35-4.31 (1H, d, J = 14.1 Hz), 3.80-3.78 (9H, m), 3.72 
(3H, s), 3.64 (3H, s), 3.05-2.99 (1H, m), 2.93-2.86 (1H, m), 2.61-2.54 (1H, m), 2.48-2.40 (1H, 
m); 13C NMR (100 MHz, CDCl3) # 174.9, 171.0, 162.5, 158.6, 157.7, 150.6, 137.8, 134.6, 132.1, 
131.6, 129.4, 128.4, 116.0, 113.8, 104.1, 98.3, 73.1, 56.9, 55.6, 55.4, 55.3, 55.2, 55.1, 51.0, 43.9, 
34.1, 29.5. 
 
 
 
methyl-(1S,4S)-2-(3,4-dimethoxybenzyl)-4-(4-methoxyphenethyl)-3,6-dioxo-2,5-
diazabicyclo[2.2.2]oct-7-ene-7-carboxylate: To a solution of cycloadduct 18 (35 mg, 0.071 
mmol) in acetic acid (1.0 mL) was added potassium iodide (35 mg, 0.212 mmol).  The reaction 
mixture was heated to 100 ºC and stirred for one hour.  The reaction mixture was washed with 
toluene (2.0 mL) and concentrated in vacuo.  The resulting residue was then quenched with 
saturated NaHCO3 solution (3.0 mL) and extracted with EtOAc (3 x 6 mL).  The organic layers 
were combined and washed with saturated NaHCO3 solution (5.0 mL), washed with 10% 
NaS2O3 solution (5.0 mL), washed with saturated NaCl solution (5.0 mL), dried with Na2SO4, 
and concentrated in vacuo.  The resulting residue was purified by flash column chromatography 
on silica gel (15% to 100% EtOAc in hexanes with constant 5% CHCl3) to afford product 19 
(13.9 mg, 41% yield) as a yellow oil.  TLC (60% EtOAc in hexanes) Rƒ = 0.55 (CAM/UV; 1H 
NMR (400 MHz, CDCl3) # 7.30-7.29 (1H, d, J = 2.3 Hz), 7.20-7.18 (2H, d, J = 8.6 Hz), 7.08-
7.06 (1H, d, J = 7.8 Hz), 6.87-6.85 (2H, d, J = 8.6 Hz), 6.40-6.37 (2H, m), 4.87-4.86 (1H, m), 
4.66-4.63 (1H, d, J = 14.5 Hz), 4.38-4.35 (1H, d, J = 14.1 Hz), 3.80 (3H, s), 3.76 (3H, s), 3.75 
(3H, s), 3.64 (3H, s), 2.87-2.84 (2H, m), 2.42-34 (2H, m); 13C (100 MHz, CDCl3) # 171.3, 169.1, 
162.1, 161.2, 158.7, 158.3, 146.2, 140.6, 132.6, 131.8, 129.3, 115.5, 114.2, 104.2, 98.3, 64.3, 
61.1, 55.32, 55.29, 55.1, 52.3, 44.5, 31.3, 28.9. 
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(1S,4S)-2-(3,4-dimethoxybenzyl)-8-(hydroxymethyl)-6-methoxy-4-(4-methoxyphenethyl)-
2,5-diazabicyclo[2.2.2]octa-5,7-dien-3-one (27): To a solution of DMB-DKP 10 (1052 mg, 2.23 
mmol) in toluene (6 mL) was added DBU (0.666 mL, 4.47 mmol) and excess propargyl alcohol 
(6 mL).  The reaction mixture was raised to 110 ºC and shown to be complete by TLC after 26 
hours.  The reaction was quenched with saturated NH4Cl solution (15 mL), and the aqueous layer 
was extracted with EtOAc (3 x 30 mL).  The organic layers were combined, washed with 
saturated NaHCO3 solution (30 mL), washed with saturated NaCl solution (30 mL), dried with 
Na2SO4, filtered, and concentrated in vacuo.  The resulting residue was purified by flash column 
chromatography on silica gel (10 to 100% EtOAc in hexanes with added constant 5% 
chloroform) to afford a largely inseparable mixture of Diels-Alder cycloadducts 27 and 28 (811 
mg, 78% yield) as a yellow oil in a ratio of 1:4.  TLC (60% EtOAc in hexanes) Rƒ = 0.60 (UV, 
CAM); IR (film) cm=1 3428, 3005, 2946, 2836, 1674, 1635, 1612, 1588, 1512, 1456, 1439, 1418, 
1351, 1332, 1293, 1245, 1209, 1179, 1158, 1121, 1035, 935, 878, 834, 757, 667, 638; 1H NMR 
(400 MHz, CDCl3) # 7.31-7.28 (1H, d, J = 8.6 Hz), 7.26-7.24 (2H, d, J = 9.4 Hz), 7.18-7.16 (2H, 
d, J = 8.2 Hz), 7.05-7.03 (1H, d, J = 8.3 Hz), 7.04-7.02 (1H, d, J = 8.3 Hz), 6.86-6.83 (2H, d, J = 
8.6 Hz), 6.84-6.82 (2H, d, J = 8.6 Hz), 6.45-6.39 (4H, m), 6.36-6.35 (1H, d, J = 2.0 Hz), 4.68 
(1H, m), 4.63-4.62 (2H, d, J = 1.9 Hz), 4.61 (2H, s), 4.49-4.45 (1H, d, J = 14.1 Hz), 4.45-4.44 
(1H, d, J = 7.5 Hz), 4.42-4.40 (1H, d, J = 7.4 Hz), 4.35-4.31 (1H, d, J = 14.4 Hz), 4.27 (1H, s), 
3.97 (1H, s), 3.80 (3H, s), 3.79 (3H, s), 3.78 (3H, s), 3.77 (3H, s), 3.73 (3H, s), 3.72 (3H, s), 3.71 
(3H, s), 3.70 (3H, s), 3.06-2.80 (4H, m), 2.57-2.49 (2H, m), 2.41-2.33 (2H, m); 13C NMR (100 
MHz, CDCl3) # 175.0, 172.6, 160.8, 158.8, 158.6, 158.5, 157.5, 147.0, 135.2, 135.0, 131.3, 
131.15, 131.11, 130.7, 130.3, 129.6, 129.4, 116.8, 115.9, 113.8, 113.7, 113.6, 104.4, 104.2, 98.5, 
98.4, 98.3, 71.8, 61.9, 61.0, 60.2, 58.2, 55.4, 55.34, 55.32, 55.3, 55.2, 52.9, 43.0, 34.3, 29.4, 27.4. 
 
 
(1S,4S)-5-(3,4-dimethoxybenzyl)-7-(hydroxymethyl)-1-(4-methoxyphenethyl)-2,5-
diazabicyclo[2.2.2]oct-7-ene-3,6-dione (29): To a solution of cycloadducts 27 and 28 (223 mg, 
0.479 mmol) in acetic acid (4 mL) was added potassium iodide (238 mg, 1.436 mmol).  The 
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reaction proceeded at 100 ºC for 1.25 hours.  The reaction mixture was diluted with toluene (5 
mL), concentrated in vacuo, redissolved in toluene (5 mL), and quenched with saturated 
NaHCO3 solution (20 mL).  The aqueous layer was extracted with EtOAc (3 x 20 mL).  The 
organic layers were combined, washed with saturated NaHCO3 solution (20 mL), 10% NaS2O3 
solution (10 mL), saturated NaCl solution (30 mL), dried with Na2SO4, and concentrated in 
vacuo.  The resulting residue was purified by flash column chromatography (40% to 100% 
EtOAc in hexanes with added constant 10% chloroform) to afford the largely inseparable 
mixture of demethylated products 29 and 30 (150 mg, 69% yield) as a yellow oil.  TLC (60% 
EtOAc in hexanes) Rƒ = 0.13 (UV, CAM); IR (film) cm-1 3405, 3232, 3007, 2937, 2837, 2248, 
1699, 1612, 1587, 1512, 1456, 1408, 1349, 1294, 1246, 1210, 1180, 1158, 1120, 1035, 911, 836, 
755, 667; 1H NMR (400 MHz, CDCl3) # 7.28 (1H, s), 7.23-7.21 (2H, d, J = 8.6 Hz), 7.20 (1H, s), 
7.19-7.16 (2H, d, J = 8.6 Hz), 7.08-7.06 (2H, d, J = 7 Hz), 7.06-7.04 (1H, d, J = 8.2 Hz), 6.85-
6.83 (2H, d, J = 8.6 Hz), 6.53-6.51 (1H, d, J = 5.9 Hz), 6.41-6.37 (4H, m), 6.29-6.28 (1H, d, J = 
1.9 Hz), 4.62-5.58 (1H, d, J = 14.4 Hz), 4.45 (1H, s), 3.37-3.33 (3H, m), 4.23-4.15 (2H, m), 4.03-
3.85 (2H, m), 3.78-3.75 (18H, m), 2.83-2.79 (2H, t, J = 7.8Hz, 8.6Hz), 2.33-2.21 (4H, m), 2.14-
2.12 (2H, t, J = 5.9Hz, 6.3Hz); 13C NMR (100 MHz, CDCl3) # 172.9, 172.8, 170.6, 170.2, 161.0, 
160.8, 158.6, 158.03, 158.0, 150.1, 133.6, 133.1, 131.4, 131.3, 131.2, 129.6, 129.5, 129.3, 116.2, 
116.0, 114.0, 113.9, 104.3, 104.2, 98.5, 98.4, 77.2, 65.5, 63.6, 62.6, 61.2, 60.9, 59.5, 55.31, 
55.27, 55.24, 55.22, 44.3, 43.5, 31.6, 29.0, 28.8. 
 
 
(1-(3,4-dimethoxybenzyl)-3-(4-methoxyphenethyl)-2-oxo-1,2-dihydropyridin-4-yl)methyl 
acetate (31): To a solution of mixed regioisomers 29 and 30 (404 mg, 0.894 mmol) in acetic 
anhydride (6 mL) was added pyridine (6 mL).  The reaction mixture was heated to 110 ºC and 
allowed to react for 48 hours.  The reaction mixture was concentrated in vacuo after adding 
toluene and chloroform.  The resulting residue was purified by flash column chromatography on 
silica gel (10% to 85% EtOAc in hexanes) to afford a largely inseparable mixture of DMB-
protected pyridones 31 and 32 (371 mg, 88% yield) as a orange-yellow oil.  TLC (60% EtOAC 
in hexanes) Rƒ = 0.57 (UV, CAM); IR (film) cm-1 3005, 2956, 2939, 2837, 1702, 1739, 1661, 
1613, 1590, 1562, 1512, 1464, 1440, 1378, 1363, 1245, 1210, 1180, 1158, 1123, 1034, 942, 830, 
755; 1H NMR (400 MHz, CDCl3) # 7.39-7.38 (1H, d, J = 2.4 Hz), 7.37-7.35 (1H, d, J = 9.0 Hz), 
7.36-7.34 (1H, d, J = 7.1 Hz), 7.30-7.28 (1H, d, J = 7.1 Hz), 7.12-7.10 (2H, d, J = 8.7 Hz), 7.12-
7.10 (2H, d, J = 7.1 Hz), 7.06-7.05 (1H, d, J = 2.7 Hz), 6.81-6.79 (2H, d, J = 8.6 Hz), 6.80-6.79 
(2H, d, J = 6.7 Hz), 6.48-6.46 (4H, m), 6.08-6.06 (1H, d, J = 7.0 Hz), 5.08 (2H, s), 5.06 (2H, s), 
4.74 (2H, s), 4.72 (2H, s), 3.83-3.78 (18H, m), 2.86-2.77 (8H, m), 2.30 (3H, s), 2.08 (3H, s), 2.04 
(3H, s); 13C NMR (100 MHz, CDCl3) 170.8, 170.5, 162.3, 160.9, 158.6, 157.7, 143.1, 137.1, 
136.3, 134.9, 134.0, 133.9, 132.7, 132.3, 132.2, 130.1, 129.6, 129.5, 129.4, 116.7, 116.6, 113.7, 
HN
DMB
N
HN
DMB
N OOO O
OH
OH
OMeOMe
+
29 30
NDMB
NDMB
O
O
OAc
AcO
MeO
MeO
31
+
32
Ac2O, pyr
110 ºC
59 
113.7, 112,7, 105.0, 104.3, 98.5, 98.4, 77.2, 63.7, 62.4, 55.4, 55.3, 55.2, 55.1, 47.5, 47.4, 33.5, 
33.4, 33.3, 29.8, 24.9, 21.0, 20.8. 
 
 
 
1-(3,4-dimethoxybenzyl)-4-(hydroxymethyl)-3-(4-methoxyphenethyl)pyridin-2(1H)-one 
(33): To a solution of pyridones 31 and 32 (40.8 mg, 0.09 mmol) in methanol (2 mL) was added 
K2CO3 (13.8 mg, 0.271 mmol).  The reaction was stirred at room temperature and found to be 
done after 1 hour by TLC.  The reaction mixture was diluted with saturated NH4Cl solution (6 
mL) and the aqueous layers were extracted with EtOAc (3 x 10 mL).  The organic layers were 
combined, washed with saturated NaCl solution (20 mL), dried with Na2SO4, and concentrated in 
vacuo.  The resulting residue was purified by flash column chromatography on silica gel (15% to 
100% EtOAc in hexanes with added constant 10% chloroform) to afford de-acetylated products 
33 and 34 (8.4 mg and 21.4 mg, 81% total yield) as a pale yellow solid (34) and pale yellow oil 
(33).  Product 33: TLC (60% EtOAc in hexanes with 10% chloroform) Rƒ = 0.25 (UV, CAM); 
IR (film) cm-1 3354, 2999, 2959, 2934, 2836, 2052, 1643, 1616, 1587, 1511, 1456, 1428, 1289, 
1245, 1209, 1179, 1158, 1123, 1085, 1033, 928, 823, 753, 668; 1H NMR (400 MHz, CDCl3) # 
7.35-7.33 (1H, d, J = 9.0 Hz), 7.31-7.30 (1H, d, J = 7.1 Hz), 7.06-7.04 (2H, d, J = 8.6 Hz), 7.80-
7.78 (2H, d, J = 8.6 Hz), 6.48-6.46 (2H, m), 6.24-6.23 (1H, d, J = 7.0 Hz), 5.08 (2H, s), 4.24-4.23 
(2H, d, J = 5.4 Hz), 3.82 (3H, s), 3.80 (3H, s), 3.77 (3H, s), 2.80 (4H, s); 13C NMR (100 MHz, 
CDCl3) # 162.4, 160.9, 158.6, 157.8, 148.0, 135.0, 134.2, 132.1, 129.7, 129.5, 128.1, 116.9, 
113.6, 104.6, 104.3, 98.5, 77.2,  61.3, 55.4, 55.3, 55.2, 47.4, 33.4, 29.3. 
 
1-(3,4-dimethoxybenzyl)-5-(hydroxymethyl)-3-(4-methoxyphenethyl)pyridin-2(1H)-one 
(34): mp 100-101ºC; TLC (60% EtOAc in hexanes with 10% chloroform) Rƒ = 0.16 (UV, 
CAM); IR (film) cm-1 3365, 3006, 2938, 2835, 1658, 1616, 1588, 1558, 1511, 1456, 1439, 1419, 
1289, 1265, 1244, 1209, 1179, 1158, 1122, 1034, 985, 824, 754, 638; 1H NMR (400 MHz, 
CDCl3) # 7.31-7.28 (1H, d, J = 9.0 Hz), 7.27 (1H, s), 7.13-7.11 (2H, d, J = 8.6 Hz), 7.11 (1H, s), 
6.81-6.79 (2H, d, J = 8.6 Hz), 6.47-6.44 (2H, m), 5.05 (2H, s), 4.33-4.31 (2H, d, J = 5.5 Hz), 3.81 
(3H, s), 3.79 (3H, s), 3.77 (3H, s), 2.84-2.79 (4H, m); 13C NMR (100 MHz, CDCl3) # 162.4, 
160.8, 158.5, 157.7, 136.5, 134.0, 133.8, 132.7, 132.0, 129.4, 117.7, 116.9, 113.6, 104.3, 98.5, 
62.5, 55.4, 55.2, 47.1, 33.5, 33.4. 
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1-(3,4-dimethoxybenzyl)-5-(4-methoxyphenethyl)-6-oxo-1,6-dihydropyridine-3-
carbaldehyde (35): To a solution of pyridone 34 (35 mg, 0.086 mmol) in dichloromethane (1.5 
mL) was added MnO2 (15 mg, 0.17 mmol).  The reaction was stirred at room temperature and 
followed by TLC.  After reacting for 1.5 hours, 15 mg (0.17 mmol) of MnO2 were added.  After 
23 hours of reacting, starting material remained by TLC and 15 mg (0.17 mmol) MnO2 were 
added.  The reaction was found to be complete by TLC after 42 hours.  The reaction mixture was 
filtered with celite, washed with dichloromethane (4 x 5 mL), and was then concentrated in 
vacuo to afford aldehyde 35 (31 mg, 89% yield) as a yellow oil.  TLC (80% EtOAc in hexanes) 
Rƒ = 0.70 (UV, CAM); IR (film) cm-1 2958, 2920, 2847, 2837, 1684, 1652, 1612, 1511, 1452, 
1436, 1390, 1288, 1245, 1209, 1177, 1158, 1134, 1033, 815; 1H NMR (400 MHz, CDCl3) # 9.49 
(1H, s), 7.92-7.91 (1H, d, J = 2.4 Hz), 7.57-7.56 (1H, d, J = 2.4 Hz), 7.40-7.38 (1H, d, J = 8.2 
Hz), 7.13-7.11 (2H, d, J = 8.6 Hz), 6.81-6.79 (2H, d, J = 8.6 Hz), 6.51-6.48 (2H, m), 5.11 (2H, s), 
3.84 (3H, s), 3.81 (3H, s), 3.78 (3H, s), 2.86-2.82 (4H, m); 13C NMR (100 MHz, CDCl3) # 186.7, 
163.1, 161.4, 158.8, 157.8, 145.3, 133.4, 133.0, 132.8, 131.5, 129.3, 117.3, 115.2, 113.7, 104.5, 
98.7, 55.4, 48.5, 33.2, 33.0. 
 
 
 
1-(3,4-dimethoxybenzyl)-3-(4-methoxyphenethyl)-2-oxo-1,2-dihydropyridine-4-
carbaldehyde (37): To a solution of pyridone 33 (15 mg, 0.037 mmol) in dichloromethane (2 
mL) was added MnO2 (10 mg, 0.110 mmol).  The reaction was stirred at room temperature and 
followed by TLC.  After 5 hours, starting material remained by TLC and 6.5 mg (0.074 mmol) 
MnO2 were added. The reaction was found to be complete by TLC after 17.5 hours.  The 
reaction mixture was filtered with celite, washed with dichloromethane (3 x 5 mL), and 
concentrated in vacuo to afford aldehyde 36 (12.5 mg, 83% yield).  TLC (60% EtOAc in 
hexanes) Rƒ = 0.64 (UV, CAM); IR (film) cm-1 3004, 2958, 2925, 2853, 2360, 2340, 1716, 
1695, 1684, 1653, 1616, 1600, 1539, 1558, 1506, 1457, 1419, 1289, 1246, 1245, 1209, 1177, 
1158, 1033, 822, 789, 668, 649; 1H NMR (400 MHz, CDCl3) # 9.84 (1H, s), 7.38-7.36 (1H, d, J 
= 7.4 Hz), 7.37-7.35 (1H, d, J = 8.2 Hz), 7.03-7.01 (2H, d, J = 8.6 Hz), 6.79-6.77 (2H, d, J = 8.6 
Hz), 6.49-6.47 (2H, m), 6.42-6.40 (1H, d, J = 7.1 Hz), 5.09 (2H, s), 3.82 (3H, s), 3.80 (3H, s), 
3.77 (3H, s), 3.25-3.21 (2H, t, J = 7.4 Hz), 2.87-2.84 (2H, t, J = 7.3 Hz); 13C NMR (100 MHz, 
CDCl3) # 190.2, 163.2, 158.7, 158.1, 139.8, 137.3, 135.6, 132.7, 132.4, 129.8, 116.1, 113.8, 
104.3, 100.7, 98.6, 76.7, 55.4, 55.2, 48.2, 34.6, 29.7, 27.4. 
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3-(4-methoxyphenethyl)-2-oxo-1,2-dihydropyridine-4-carbaldehyde (38): To a solution of 
product 37 (22.4mg, 0.055 mmol) in CH2Cl2 (0.5 mL) was added trifluoracetic acid (0.25 mL).  
The reaction mixture was heated in the microwave (temperature mode = 130 ºC, 30 min). The 
reaction mixture was concentrated in vacuo and purified by flash column chromatography on 
silica gel (0% to 10% methanol in CHCl3) to afford pyridone 38 (11.6 mg, 83% yield) as a 
yellow solid. mp 134-136ºC; TLC (3% methanol in CHCl3) Rƒ = 0.25 (UV, CAM); IR (film) 
cm-1 3271, 3145, 3001, 2957, 2916, 1849, 2252, 1696, 1653, 1617, 1558, 1512, 1457, 1301, 
1248, 1206, 1177, 1108, 1037, 910, 812, 732, 649; 1H NMR (400 MHz, CDCl3) # 9.80 (1H, s), 
7.34-7.33 (1H, d, J = 6.6 Hz), 7.02-7.00 (2H, d, J = 8.6 Hz), 6.81-6.78 (2H, d, J = 8.6 Hz), 6.58-
6.57 (1H, d, J = 6.7 Hz), 3.77 (3H, s), 3.26-3.22 (2H, t, J = 7.0, 7.4 Hz), 2.91-2.87 (2H, t, J = 7.0, 
7.4 Hz); 13C (100 MHz, CDCl3) # 189.7, 158.3, 141.9, 132.3, 131.9, 129.8, 113.9, 102.6, 77.2, 
55.3, 38.1, 34.5, 31.2, 29.7, 26.7. 
 
 
 
3-(4-hydroxyphenethyl)-2-oxo-1,2-dihydropyridine-4-carbaldehyde (39): To a solution of 
pyridone 38 (11.0 mg, 0.043mmol) in CH2Cl2 (1 mL) cooled to -78 ºC was added BBr3 (0.128 
mL, 0.128 mmol) dropwise.  The reaction mixture was allowed to warm to room temperature and 
was stirred for 4 hours.  The reaction was diluted and quenched with saturated sodium 
bicarbonate solution (5 mL).  It was then extracted with EtOAc (5 x 5mL).  The organic layers 
were combined and washed with saturated NaCl solution (10 mL), dried with Na2SO4, and 
concentrated in vacuo.  The resulting residue was purified by flash column chromatography on 
silica gel (0% to 7% methanol in EtOAc) to afford pyridone 9 (3.9 mg, 38% yield) as a pale 
yellow solid. TLC (100% EtOAc) Rƒ = 0.11 (UV, CAM). 
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The End! 
